US5874600A - Ruthenium catalysts and their use in the asymmetric hydrogenation of cyclopentenones - Google Patents

Ruthenium catalysts and their use in the asymmetric hydrogenation of cyclopentenones Download PDF

Info

Publication number
US5874600A
US5874600A US08/875,335 US87533597A US5874600A US 5874600 A US5874600 A US 5874600A US 87533597 A US87533597 A US 87533597A US 5874600 A US5874600 A US 5874600A
Authority
US
United States
Prior art keywords
catalyst
coordinating
duphos
substrate
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US08/875,335
Inventor
Valentin Rautenstrauch
Koenraad P. M. Vanhessche
Jean-Pierre Genet
Jean-Yves Lenoir
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Firmenich SA
Original Assignee
Firmenich SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Firmenich SA filed Critical Firmenich SA
Assigned to FIRMENICH S.A. reassignment FIRMENICH S.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: VANHESSCHE, P.M., GENET, JEAN-PIERRE, LENOIR, JEAN-YVES, RAUTENSTRAUCH, VALENTIN
Application granted granted Critical
Publication of US5874600A publication Critical patent/US5874600A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/18—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms
    • B01J31/1845—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms the ligands containing phosphorus
    • B01J31/1875—Phosphinites (R2P(OR), their isomeric phosphine oxides (R3P=O) and RO-substitution derivatives thereof)
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/22—Organic complexes
    • B01J31/2282—Unsaturated compounds used as ligands
    • B01J31/2295—Cyclic compounds, e.g. cyclopentadienyls
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B01J31/2404—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
    • B01J31/2409—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring with more than one complexing phosphine-P atom
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B01J31/2404—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
    • B01J31/2419—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising P as ring member
    • B01J31/2428—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising P as ring member with more than one complexing phosphine-P atom
    • B01J31/2433—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising P as ring member with more than one complexing phosphine-P atom comprising aliphatic or saturated rings
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B01J31/2404—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
    • B01J31/2442—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems
    • B01J31/2447—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems and phosphine-P atoms as substituents on a ring of the condensed system or on a further attached ring
    • B01J31/2452—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems and phosphine-P atoms as substituents on a ring of the condensed system or on a further attached ring with more than one complexing phosphine-P atom
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B01J31/2404—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
    • B01J31/2442—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems
    • B01J31/2447—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems and phosphine-P atoms as substituents on a ring of the condensed system or on a further attached ring
    • B01J31/2452—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems and phosphine-P atoms as substituents on a ring of the condensed system or on a further attached ring with more than one complexing phosphine-P atom
    • B01J31/2457—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems and phosphine-P atoms as substituents on a ring of the condensed system or on a further attached ring with more than one complexing phosphine-P atom comprising aliphatic or saturated rings, e.g. Xantphos
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/303—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by hydrogenation of unsaturated carbon-to-carbon bonds
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/60—Reduction reactions, e.g. hydrogenation
    • B01J2231/64—Reductions in general of organic substrates, e.g. hydride reductions or hydrogenations
    • B01J2231/641—Hydrogenation of organic substrates, i.e. H2 or H-transfer hydrogenations, e.g. Fischer-Tropsch processes
    • B01J2231/645—Hydrogenation of organic substrates, i.e. H2 or H-transfer hydrogenations, e.g. Fischer-Tropsch processes of C=C or C-C triple bonds
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/02—Compositional aspects of complexes used, e.g. polynuclearity
    • B01J2531/0202—Polynuclearity
    • B01J2531/0205—Bi- or polynuclear complexes, i.e. comprising two or more metal coordination centres, without metal-metal bonds, e.g. Cp(Lx)Zr-imidazole-Zr(Lx)Cp
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80—Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82—Metals of the platinum group
    • B01J2531/821—Ruthenium
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80—Complexes comprising metals of Group VIII as the central metal
    • B01J2531/84—Metals of the iron group
    • B01J2531/842—Iron
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/22—Organic complexes
    • B01J31/2282—Unsaturated compounds used as ligands
    • B01J31/2291—Olefins

Definitions

  • the present invention relates to the field of asymmetric hydrogenation in homogeneous conditions and, more particularly, to the use of novel Ru(II) chiral catalysts for the asymmetric hydrogenation of cyclopentenone derivatives having the general formula ##STR1## wherein R 1 represents a linear or branched C 1 to C 4 alkyl radical and R 2 represents a saturated or unsaturated, linear or branched, C 1 to C 8 hydrocarbon radical.
  • the compounds of formula (II) are substrates the asymmetric and stereospecific hydrogenation of which had proved heretofore impossible as a result of their weak donor capability and of their hindered structure, and this in spite of all the progress in homogeneous catalysis achieved in recent years.
  • Such catalysts were obtained by heating the above-mentioned Ru(II) complex together with the appropriate diphosphine ligand, in a solvent such as hexane or toluene, such as to replace the cyclooctadiene with the chiral phosphine.
  • This kind of catalysts which can be prepared in situ, proved to be useful for the asymmetric hydrogenation, in protic or strongly electron-donating solvents (methanol, ethanol, THF, or their mixtures with other solvents), of substrates comprising carbonyl groups and acyclic ethylenic bonds.
  • protic or strongly electron-donating solvents methanol, ethanol, THF, or their mixtures with other solvents
  • methyl 3-oxo-2-pentyl-1-cyclopentene-1-acetate is particularly interesting in the context of the invention, inasmuch as its asymmetric hydrogenation could potentially provide, in a single step, the optically active isomers of methyl dihydrojasmonate or Hedione® (origin: Firmenich SA, Geneva, Switzerland), a prized perfuming ingredient.
  • methyl (+)-(1R)-cis-3-oxo-2-pentyl-1-cyclopentaneacetate is known to possess at their best the odor characters, and namely the jasmine note, for which Hedione® is prized, the strength of this isomer's odor being also superior to that of the other isomers by several orders of magnitude. Therefore, the production of methyl (+)-(1R)-cis-3-oxo-2-pentyl-1-cyclopentaneacetate in an optically pure state, or of isomer mixtures which contain essentially this isomer, is of capital importance in the fragrance industry. Yet, there is at present no synthesis of this compound which is susceptible of industrial application, starting from a substrate such as cited above, all efforts to asymmetrically hydrogenate said substrate having met with failure up until now.
  • the aim of the present invention is to provide precisely a solution to this problem.
  • An object of the present invention is therefore a ruthenium (II) catalyst comprising bidentate phosphine ligands, characterized in that said catalyst is obtainable by a process which comprises treating equimolar amounts of an appropriate Ru(II) complex and a bidentate diphosphine ligand with an acid of the formula HX, wherein X is a non-coordinating anion, said acid being used in a ratio which does not exceed 2 molar equivalents per mole of Ru(II) complex and the treatment being carried out in a non-coordinating or weakly coordinating solvent and under an inert atmosphere.
  • an “appropriate Ru(II) complex” it is meant here any Ru(II) complex wherein the metal is surrounded by dienyl and alkyl type ligands, such that the metal is ⁇ -bonded to two of said ligands, which ligands further possess at least one bond ⁇ -bonded to the metal, two other metal coordination positions being ⁇ -bonded to the same said two ligands or to a distinct ligand.
  • ruthenium(II) complexes the compounds of the (diene)Ru(allyl) 2 ! type, wherein “diene” stands for example for COD (cycloocta-1,5-diene) or NBD (norbornadiene), or yet hepta-1,4-diene, and “allyl” represents a 2-propenyl or 2-methallyl radical (see, for instance, J.-P. Genet et al., cited references; M. O. Albers et al., Inorganic Synth. 1989, 26, 249; R. R. Schrock et al., J. Chem. Soc. Dalton Trans, 1974, 951).
  • ruthenium(II) complexes include the compounds of the bis(pentadienyl)Ru! type, wherein "pentadienyl” represents a 2,4-dimethylpentadienyl, 2,3,4-trimethylpentadienyl, 2,4-di(tert-butyl) pentadienyl or yet 2,4-dimethyl-1-oxapentadienyl radical (see, for example, R. D. Ernst et al., J. Organometallic Chem., 1991, 402, 17; L. Stahl et al., Organometallic 1983, 2, 1229 ; T. Schmidt et al., J. Chem. Soc. Chem. Commun., 1991, 1427; T. D. Newbound et al., Organometallics, 1990, 9, 2962).
  • the Ru(II) precursor there is used as the Ru(II) precursor, the compound of formula (COD)Ru(2-methallyl) 2 !, the bis(2,4-dimethylpentadienyl)ruthenium (e.g. L. Stahl et al. or T. D. Newbound et al., refs cited) or the bis(2,4-dimethyl-1-oxapenta-dienyl)ruthenium complexes (e.g. T. Schmidt et al., ref. cited).
  • the bis(2,4-dimethylpentadienyl)ruthenium e.g. L. Stahl et al. or T. D. Newbound et al., refs cited
  • the bis(2,4-dimethyl-1-oxapenta-dienyl)ruthenium complexes e.g. T. Schmidt et al., ref. cited.
  • bidentate phosphines which can be used as ligands in the catalysts of the invention, there can be cited, as preferred embodiments, those selected from the group consisting of the chiral phosphines known under the abbreviations of Me-DuPHOS, Et-DuPHOS, BINAP, To1BINAP, SKEWPHOS, DIPAMP and CHIRAPHOS, the structures of which are represented hereafter for one of the enantiomers in particular: ##STR2##
  • chiral bidentate phosphines which can be used in the chiral catalysts of the invention include for instance those known under the name of NORPHOS, or yet analogues of the DuPHOS type ligands, so-called "BPE", the structures of which are represented hereafter for one of the enantiomers. ##STR3##
  • any bidentate diphosphine comprising substituent groups capable of rendering said diphosphine sufficiently electron-rich to allow it to stabilize the metal, without however depriving said metal from its ability to coordinate substrate (II).
  • diphosphines having a certain number of alkyl or cycloalkyl type substituents revealed themselves particularly useful for the aim of the invention and provided catalysts which were very active and efficient for the hydrogenation of substrates (II).
  • the preferred ligands for preparing the catalysts of the invention are diphosphine ligands in which the two phosphorous atoms are bridged by groups of the alkyl, 1,2-benzenyl, bis(naphtalenyl) or yet 1,1'-ferrocenyl type, optionally substituted, said phosphorous atoms further carrying two other substituents, which can be identical or different and formed of alkyl, aryl or alkylaryl radicals, or yet alicyclic radicals.
  • the catalysts of the invention which comprise diphosphine ligands of the DuPHOS, BINAP, To1BINAP, SKEWPHOS or JOSIPHOS type are particularly advantageous as catalysts for the asymmetric hydrogenation of the substrates of formula (II), as is apparent from the examples presented further on.
  • the ligands of the type L1 to L13 represented below are either commercially available compounds or they can be prepared according to processes analogous to previously described methods.
  • the ligands of the DuPHOS, SKEWPHOS, BINAP, CHIRAPHOS, DIPAMP and NORPHOS type are mostly commercial products and, in any event, they can be obtained via processes described in the literature, namely in reference works such as the books of R. Noyori, Asymmetric Catalysis in Organic Synthesis, John Wiley & Sons, N.Y (1994), Chap. II and J. Ojima, Catalytic Asymmetric Synthesis, VCH Publishers, N.Y. (1994), Chap. I.
  • the above-mentioned acids of formula HX used for the preparation of the catalysts of the invention, are typically used in the form of the corresponding etherates (for example HBF 4 .R 2 O, R ⁇ CH 3 or C 2 H 5 ) or of any other onium type salt (phosphonium or sulfonium, for example).
  • These etherates are commercial products, or they can be prepared from the corresponding silver salts, by reacting with HCl.
  • the silver salt for example AgBF 4 , AgPF 6 , AgSbF 6 or AgAsF 6 will be typically reacted with HCl, in a solvent containing a dialkylether, for example a mixture of dichloromethane and diethylether.
  • the silver chloride precipitates, it provides the etherate solution of the acid, with is then used according to the invention in the reaction with the ruthenium complex and the phosphine ligand.
  • HX acid As the HX acid, one can cite an acid selected from the group consisting of HBF 4 , HPF 6 , HSbF 6 , HAsF 6 , and HB 3,5-(CF 3 ) 2 C 6 H 4 ! 4 . All these acids have as common characteristic the fact that their anion is non-coordinating.
  • tetrafluoroboric acid etherate there is used tetrafluoroboric acid etherate.
  • the reaction which characterizes the process for the preparation of the invention's catalysts takes place in a non-coordinating or weakly coordinating medium, under inert atmosphere.
  • a non-coordinating or weakly coordinating medium under inert atmosphere.
  • non-coordinating or weakly coordinating medium it is meant here for example, a non-coordinating or weakly coordinating solvent. It may also be meant moreover that the reaction occurs in a solvent as defined above, but also in the presence of the above-cited substrate of formula ##STR7## wherein R 1 represents a linear or branched C 1 to C 4 alkyl radical and R 2 represents a saturated or unsaturated, linear or branched, C 1 to C 8 hydrocarbon radical.
  • the latter will be preferably selected from the group consisting of dichloromethane, dichloroethane, ethyl pivalate, methyl acetate, ethyl acetate, isopropyl acetate, acetone, 2-butanone, 3-pentanone and any mixture of two or several of these solvents.
  • dichloromethane or a mixture of the latter with other, non-coordinating or weakly coordinating solvents, in particular those mentioned above, is used.
  • the catalysts comprising the chiral ligands previously cited proved to be particularly useful for the preparation of optically active compounds of formula (I), in particular of methyl (+)-(1R)-cis-3-oxo-2-pentyl-1-cyclopentaneacetate.
  • the preparation of the catalyst can take place at room temperature or a lower temperature.
  • the temperature of the above-mentioned treatment does not seem to be a critical parameter of the process, susceptible of affecting the catalyst's properties and its efficiency in the hydrogenation of the substrates (II).
  • the application of room temperature is of course advantageous from a practical point of view.
  • the ratio between the molecular weight of the HX acid, for example HBF 4 , HPF 6 , HSbF 6 ou HAsF 6 , and the molecular weight of the ruthenium complex is a critical parameter which determines the catalyst's characteristics and its efficiency in the asymmetrical hydrogenation of the above-mentioned substrates according to the present invention, and more particularly of methyl 3-oxo-2-pentyl-1-cyclopentene-1-acetate.
  • This is all the more surprising in that the prior art is totally silent on this subject.
  • known studies often report the use of a substantial excess of acid, relative to the amount required to form the cationic ruthenium complex in the presence of the bidentate phosphine ligand.
  • the use of an excess of acid renders the catalysts inactive or inefficient in the context of the present invention.
  • the acid will be preferably used in a ratio from 1.5 to 2 mole equivalents, per mole of the Ru(II) complex. More preferably, the ratio between these two reagents will be about 2 mole equivalents of acid per mole of complex.
  • the invention also concerns a process for the preparation of Ru(II) catalysts, characterized in that equimolar amounts of an appropriate Ru(II) complex and a bidentate diphosphine ligand are reacted, under an inert atmosphere and in a non-coordinating or weakly coordinating medium, with an acid of formula HX, wherein X is a non-coordinating anion, the acid being employed in a ratio which does not exceed 2 molar equivalents per mole of Ru(II) complex.
  • the appropriate Ru(II) complexes, and in particular the preferred complex (COD)Ru(2-methylallyl) 2 !, which are used as starting products in the process for the preparation of the catalysts according to the present invention, are typically known compounds which can be prepared as is described in the above-cited prior art documents, or by processes which are analogous to those known.
  • the phosphines which form the ligands of the catalyts according to the present invention, and which determine their chirality are either commercially available compounds or can be prepared by known methods.
  • the preparation of the catalyst can be executed in a medium which is constituted by a solvent or a mixture of the solvent with the substrate (II).
  • This last embodiment, as well as that according to which the catalyst is prepared in the presence of only the substrate (II), are methods particularly suitable for the in situ preparation of the catalysts, in the medium of the hydrogenation reaction, described further on.
  • the catalysts according to the present invention are obtained as solutions in the solvent and/or the substrate (II) of the product which is the result of the reaction of the Ru(II) complex with the diphosphine ligand and the HX acid.
  • These catalytic solutions may be used as such for the asymmetric hydrogenation of substrates (II). They can be kept under an inert atmosphere and will stay active for several days. Moreover, they may also be concentrated under vacuo to give the catalysts in a solid form.
  • the catalysts can also be generated in situ in the hydrogenation medium, as will become apparent below.
  • Catalytic solutions according to the present invention are thus obtained, having a variable concentration in the catalyst according to the present invention, for example of the order of 0.01M (0.01 moles of catalyst/1 of catalytic solution), which proved to be very advantageous in the hydrogenation of substrates (II).
  • very good catalysts were also obtained by first mixing the diphosphine ligand, in particular (-)-Me-DuPHOS, with the acid of formula HX, in the form of an etherate or an onium salt, in particular HBF 4 -etherate, for example in dichloromethane.
  • the product thus obtained may be reduced to the form of a solid onium salt by removing under vacuo the ether and CH 2 Cl 2 , and thereafter be used in the reaction with the Ru(II) complex in a solvent to give the desired catalysts.
  • This embodiment is quite useful in practice, as it allows separate preparation of the salts of the ligands, which thereafter can react with the Ru(II) complex.
  • the dicationic compounds of Ru(II) according to the invention prove to be very useful as catalysts in hydrogenation reactions.
  • they show an excellent efficiency in the conversion of substrates (II), and the invention therefore also concerns a process for the preparation of a compound of formula ##STR9## in which R 1 represents a linear or branched alkyl radical from C 1 to C 4 and R 2 represents a saturated or unsaturated hydrocarbon rest, linear or branched, from C 1 to C 8 , essentially in the form of an isomer of cis configuration, characterized in that a substrate of formula ##STR10## in which R 1 and R 2 have the meaning indicated above, is catalytically hydrogenated in the presence of a Ru(II) catalyst according to the present invention as previously described, and at a hydrogen pressure of from 10 to 100 bar (2 to 10 ⁇ 10 6 Pa).
  • the catalyst is generated in situ before the hydrogenation of substrate (II) or, optionally, in the presence of the latter, by treating equimolar amounts of the Ru(II) complex, in particular the compound of formula (COD)Ru(2-methylallyl) 2 !, and an appropriate chiral bidentate phosphine ligand, selected, for example, from the group consisting of the diphosphines which are known under the abbreviations of Me-DuPHOS, Et-DuPHOS, BINAP, To1BINAP, SKEWPHOS, DIPAMP, CHIRAPHOS and JOSIPHOS, with the etherate of tetrafluoroboric acid in a proportion of about 2 molar equivalents of HBF 4 per mole of Ru(II) complex.
  • This preferred embodiment enables the preparation of the above-mentioned compound (I) in the form of an optically active isomer of (1R)-cis configuration.
  • racemic or achiral ligands provide catalysts which make it possible to obtain the compounds (I) in the form of the racemic cis-isomer.
  • racemic ligands for example L8 and L9
  • their corresponding enantiomers can be obtained by separation of the racemic ligand, and these enantiomers of the ligand may thereafter serve to prepare optically active catalysts according to the invention.
  • the preparation of the catalyst takes place in the absence of substrate (II)
  • the catalytic solution thus obtained will then be used in the hydrogenation of substrate (II).
  • a hydrogenation medium which comprises a solvent preferably the same solvent as that in which the catalyst has been obtained is used.
  • a chlorinated hydrocarbon like dichloromethane, dichlororethane or a mixture of both.
  • dichloromethane optionally in a mixture with the other solvents which have been cited above, has proved to be very advantageous according to the invention.
  • methyl 3-oxo-2-pentyl-1-cyclopentene-1-acetate is used as a substrate in order to obtain Hedione® in the form of the preferred (+)-cis-configuration isomer.
  • the catalysts according to the present invention which have ligands of the DuPHOS type, and in particular Me-DuPHOS, have proved to be particularly useful for the hydrogenation of this substrate.
  • the hydrogenation which characterizes the process according to the invention is carried out under a hydrogen pressure which can vary from 10 to 100 bar (2 to 10 ⁇ 10 6 Pa). Pressures from 70 to 100 bar, in particular from 90 to 100 bar, are preferred.
  • the reaction may take place at temperatures of up to 50° to 60° C., or even 100° C. Preferably, one will work at room temperature or a lower temperature. It has been found that temperatures of down to -10° C., or even lower, made it possible to obtain very useful results.
  • the molar concentrations of the Ru(II) catalyst with respect to the substrate typically vary from 0.01 to 4 mole %, preferably from 0.1 to 2 mole %. According to a more preferred embodiment, they shall be of the order of 0.3 or 0.4 mole %.
  • a trialkylamine preferably diisopropylethylamine (DIPEA)
  • DIPEA diisopropylethylamine
  • concentration in which this base may be added to the reaction medium varies in a molar ratio of from 0.1:1 to 0.5:1, relative to the Ru(II) catalyst. The best yields of final product were obtained when diisopropylamine was added in a proportion of 0.2 equivalents with respect to the catalyst.
  • the substrate which is to be hydrogenated is first mixed with the equimolar mixture of (COD)Ru(2-methylallyl) 2 ! and diphoshine ligand, optionally in a solvent, and thereafter HBF 4 -etherate or another salt of a HX acid is added to the thus obtained solution, in the proportion mentioned above.
  • the thus obtained reaction medium is thereafter pressurized under hydrogen in a conventional manner, as will be described in the examples below.
  • This etherate or another salt of the onium type can be added as such or in the form of a solution, and either in the same solvent as that previously used, or in a different solvent.
  • the invention thus provides new catalysts and processes for the use of these catalysts which allow the preparation, in a single step, and under conditions which are advantageous and susceptible of industrial application, of products useful in perfumery, in a stereoselective manner and, as the case may be, enantioselective, and in excellent yields.
  • the catalysts of the present invention are capable of hydrogenating substrates (II) with very fast reaction speeds, substrate conversion rates above 98% and providing essentially the diastereomer of (1R)-cis configuration of the desired compounds.
  • the solution may also be concentrated under vacuo to provide the catalyst in a solid form.
  • Optically active catalysts were thus prepared with the following ligands: (+)-(S,S)-Me-DuPHOS; (-)-(R,R)-Me-DuPHOS; (+)-(S,S)-Et-DuPHOS; (-)-(R,R)-Et-DuPHOS; (+)-(R)-BINAP; (-)-(S)-BINAP; (-)-(R,R)-NORPHOS; (-)-(S,S)-CHIRAPHOS; (+)-(R,R)-CHIRAPHOS; (-)-(S,S)-SKEWPHOS; (+)-(R,R)-SKEWPHOS; (+)-(R,R)-DIPAMP; (+)-(S,S)-DIPAMP; (-)-(S)-To1BINAP; (+)-(R)-To1BINAP; (-)-(R)-(S)-JOSIPHOS et (+
  • the ligands L13 mentioned above are commercially available (origin: Fluka Chemie and Aldrich), as is the ligand of type L12 cited above (origin: Strem Chemicals).
  • the above mentioned ligands of the L8, L9 and L10 type were prepared according to known methods (see references cited above and I. R. Butter et al., Synth. React. Inorg. Met. -Org. Chem. 1985, 15, 109) from ferrocene and according to the following reaction schemes: ##STR11##
  • a glass beaker adapted for use in an autoclave was charged with the catalyst solution obtained as described in example 1, the above-mentioned substrate which had been prior degassed, and the degassed solvent.
  • the beaker containing a stirring rod was introduced in the autoclave inside the glove box, and the autoclave was sealed before being taken out of the glove box to be pressurized.
  • the inlets of the autoclave were purged with H 2 and thereafter pressurized to the chosen value.
  • the reaction was allowed to occur at room temperature.
  • the pressure was released under air, the autoclave was opened and the solution concentrated under reduced pressure.
  • the catalyst was precipitated with pentane, filtered and the filtrate was concentrated to provide the desired Hedione®.
  • the product can be purified by distillation in a bulb-to-bulb apparatus (150°-200° C./5 Pa) without changing the diastereomeric ratio.
  • Table I gives a summary of the results of the different runs which were carried out under various conditions and with catalysts which had been prepared as described in example 1, by means of the chiral ligands indicated in table I.
  • the substrate mentioned in example 2 was hydrogenated according to a method analogous to that described above, by proceeding as follows.
  • the beaker containing a stirring rod was introduced in the autoclave inside the glove box, and the autoclave was closed before being pressurized outside the glove box.
  • the inlets of the autoclave were purged with H 2 and thereafter pressurized at 2 ⁇ 10 6 Pa.
  • the reaction was allowed to proceed at room temperature for 17 h.
  • the autoclave was degassed and opened and the solution concentrated under reduced pressure.
  • the catalyst was precipitated with pentane, filtered and the resulting filtrate concentrated to obtain the desired Hedione®.
  • Table II summarizes the results which were obtained in the hydrogenation reactions carried out with different catalysts (variation of the nature of the ligand) in the concentrations indicated, a hydrogen pressure of about 100 bar (10 ⁇ 10 6 Pa), room temperature and a reaction time of about 22 h.
  • Table III summarizes the results which were obtained with different catalysts (variation of the nature of the ligand) and by varying several reaction parameters. All reactions were carried out at room temperature, unless otherwise indicated.
  • the catalysts according to the invention were prepared using (-)-Me-DuPHOS as ligand and varying on the nature of the acid of formula HX.
  • the respective acids HBF 4 , HPF 6 , HSbF 6 and HAsF 6 (as etherates) were prepared by reacting 0.2 mmole of the corresponding silver salt in 0.8 ml of dichloromethane, using 0.2 ml of a 1M anhydrous solution of HCl 1M in ether.
  • step C Inside the glove box, 224 mg (1 mmole) of methyl 3-oxo-2-pentyl-1-cyclopentene-1-acetate were added to 2 ml of the catalytic solution obtained in step B (0.02 mmole, 2 mole % with respect to the substrate) in a glass beaker which can be transferred to an autoclave. The solution thus obtained was then transferred into an autoclave and stirred for 2 h at 90 bar (9 ⁇ 10 6 Pa) hydrogen pressure at room temperature. The autoclave was almost entirely degassed and opened inside the glove box. The yellow-orange reaction mixture was evaporated under vacuo to strip the dichloromethane.
  • the solid residue and the yellow-orange liquid thus obtained were treated with pentane and the suspension filtered through a Teflon® filter of 0.22 ⁇ to precipitate the catalyst. The remaining solid was washed with pentane and filtered through the same filter.
  • the catalyst was also prepared as follows: the HBF 4 .Et 2 O solution in dichloromethane described under A was first added to (-)-Me-DuPHOS, and the ether and the dichloromethane were evaporated. The thus obtained solid of the onium salt of the ligand was then redissolved in pure dichloromethane and added to Ru(COD)(2-methallyl) 2 !. The reaction occurs with release of isobutene. The catalyst thus obtained was used under conditions identical to those described under C to give (+)-cis-Hedione® having the same characteristics.
  • the hydrogenation reaction was carried out at 7,5° C. and under a hydrogen pressure of 35 bar (3.5 ⁇ 10 6 Pa) for 24 h, under stirring (1000-2000 rpm).

Abstract

A catalyst of ruthenium (II) which includes bidentate phosphine ligands. The catalyst is obtainable by a process which includes the steps of treating equimolar amounts of an appropriate Ru(II) complex and a bidentate diphosphine ligand with an acid of formula HX, wherein X is a non-coordinating anion. The acid is used in a ratio which does not exceed 2 molar equivalents per mole of Ru(II) complex and the treatment is carried out in a non-coordinating or weakly coordinating solvent and under an inert atmosphere. This catalyst is useful for the preparation of the preferred isomer of HEDIONE, having the (+)-(1R)-cis-configuration.

Description

TECHNICAL FIELD
The present invention relates to the field of asymmetric hydrogenation in homogeneous conditions and, more particularly, to the use of novel Ru(II) chiral catalysts for the asymmetric hydrogenation of cyclopentenone derivatives having the general formula ##STR1## wherein R1 represents a linear or branched C1 to C4 alkyl radical and R2 represents a saturated or unsaturated, linear or branched, C1 to C8 hydrocarbon radical.
The compounds of formula (II) are substrates the asymmetric and stereospecific hydrogenation of which had proved heretofore impossible as a result of their weak donor capability and of their hindered structure, and this in spite of all the progress in homogeneous catalysis achieved in recent years.
PRIOR ART
A great number of chiral catalysts useful for asymmetric hydrogenations is in fact known at present. In the context of the present invention, we can cite in particular the efforts of two research groups which actively studied the synthesis of Ru(II) chiral catalysts, obtained from the Ru(II) complex of formula (COD)Ru(2-methylallyl)2 !(COD=cyclo-1,5-octadiene).
Thus, J.-P. Genet and his collaborators have published work related to catalysts of formula Ru(P*--P*)(2-methylallyl)2 !, wherein P*--P* represents a bidentate ligand of the type of those currently known under abbreviated designations such as DIOP, CHIRAPHOS, PROPHOS, BDPP, CBD, NORPHOS, DEGUPHOS, BPPM, BINAP, R-DuPHOS (R=methyl or ethyl), BIPHEMP or yet DIPAMP (see, for example, J.-P. Genet et al., Tetrahedron: Asymmetry 1991, 2, 43). Such catalysts were obtained by heating the above-mentioned Ru(II) complex together with the appropriate diphosphine ligand, in a solvent such as hexane or toluene, such as to replace the cyclooctadiene with the chiral phosphine.
Upon subsequent work (see, for example, WO 91/02588; J.-P. Genet, Acros Organics Acta, 1994, 1, 1-8; J.-P. Genet et al., Tetrahedron : Asymmetry, 1994, 5, 665-690), these authors described the transformation of such catalysts via protonation by means of aqueous acids such as HBr, HCl, HF or HBF4, in strongly coordinating solvents, capable of playing a role in stabilizing the coordination structure around the metal, which structure, according to the same authors, is of the hexacoordinate type. This kind of catalysts, which can be prepared in situ, proved to be useful for the asymmetric hydrogenation, in protic or strongly electron-donating solvents (methanol, ethanol, THF, or their mixtures with other solvents), of substrates comprising carbonyl groups and acyclic ethylenic bonds.
Other studies (see, for example, F. Heiser et al., Tetrahedron: Asymmetry, 1991, 2, 51-62; EP 643 052; EP 398 132; EP 570 674) have resulted in reports of the use of catalysts prepared in situ for hydrogenating a variety of substrates, starting from the same ruthenium complex, but following a process according to which a mixture of said complex and an appropriate diphosphine ligand is treated with namely CF3 COOH, once again in an electron-donor solvent able to stabilize the coordinating structure of the metal.
These catalysts, and others obtained according to similar processes described in the cited references, reveal themselves very efficient in the asymmetric hydrogenation of various substrates, often good electron-donor substrates capable of coordinating the Ru(II), and are typically used with protic solvents, or mixtures of protic and aprotic solvents. However, they proved to be inefficient with regard to the hydrogenation of substrates (II) cited above, when prepared according to the prior art methods and used under the reported conditions. In fact, substrates (II) are weak electron-donors, when compared to the type of substrates described in the prior art, and the many attempts carried out heretofore in an effort to asymmetrically hydrogenate them had always proved fruitless.
It should be pointed out that, among the formula (II) substrates, methyl 3-oxo-2-pentyl-1-cyclopentene-1-acetate is particularly interesting in the context of the invention, inasmuch as its asymmetric hydrogenation could potentially provide, in a single step, the optically active isomers of methyl dihydrojasmonate or Hedione® (origin: Firmenich SA, Geneva, Switzerland), a prized perfuming ingredient.
Amongst the four possible Hedione® stereoisomers, methyl (+)-(1R)-cis-3-oxo-2-pentyl-1-cyclopentaneacetate is known to possess at their best the odor characters, and namely the jasmine note, for which Hedione® is prized, the strength of this isomer's odor being also superior to that of the other isomers by several orders of magnitude. Therefore, the production of methyl (+)-(1R)-cis-3-oxo-2-pentyl-1-cyclopentaneacetate in an optically pure state, or of isomer mixtures which contain essentially this isomer, is of capital importance in the fragrance industry. Yet, there is at present no synthesis of this compound which is susceptible of industrial application, starting from a substrate such as cited above, all efforts to asymmetrically hydrogenate said substrate having met with failure up until now.
DESCRIPTION OF THE INVENTION
The aim of the present invention is to provide precisely a solution to this problem.
We have now discovered that this preferred isomer of Hedione® can be prepared in excellent diastereochemical and enantiomeric purity, by way of a one-step process, resorting to the use of novel Ru(II) chiral catalysts, produced by means of an original method.
An object of the present invention is therefore a ruthenium (II) catalyst comprising bidentate phosphine ligands, characterized in that said catalyst is obtainable by a process which comprises treating equimolar amounts of an appropriate Ru(II) complex and a bidentate diphosphine ligand with an acid of the formula HX, wherein X is a non-coordinating anion, said acid being used in a ratio which does not exceed 2 molar equivalents per mole of Ru(II) complex and the treatment being carried out in a non-coordinating or weakly coordinating solvent and under an inert atmosphere.
By an "appropriate Ru(II) complex" it is meant here any Ru(II) complex wherein the metal is surrounded by dienyl and alkyl type ligands, such that the metal is σ-bonded to two of said ligands, which ligands further possess at least one bond π-bonded to the metal, two other metal coordination positions being π-bonded to the same said two ligands or to a distinct ligand.
Several ruthenium compounds, or analogous compounds of other transition metals, are known from the prior art which comprise ligands fulfilling the above-mentioned conditions and which are convenient as precursors of the catalysts of the present invention.
One can cite more particularly, as appropriate ruthenium(II) complexes, the compounds of the (diene)Ru(allyl)2 ! type, wherein "diene" stands for example for COD (cycloocta-1,5-diene) or NBD (norbornadiene), or yet hepta-1,4-diene, and "allyl" represents a 2-propenyl or 2-methallyl radical (see, for instance, J.-P. Genet et al., cited references; M. O. Albers et al., Inorganic Synth. 1989, 26, 249; R. R. Schrock et al., J. Chem. Soc. Dalton Trans, 1974, 951). Other appropriate ruthenium(II) complexes include the compounds of the bis(pentadienyl)Ru! type, wherein "pentadienyl" represents a 2,4-dimethylpentadienyl, 2,3,4-trimethylpentadienyl, 2,4-di(tert-butyl) pentadienyl or yet 2,4-dimethyl-1-oxapentadienyl radical (see, for example, R. D. Ernst et al., J. Organometallic Chem., 1991, 402, 17; L. Stahl et al., Organometallic 1983, 2, 1229 ; T. Schmidt et al., J. Chem. Soc. Chem. Commun., 1991, 1427; T. D. Newbound et al., Organometallics, 1990, 9, 2962).
Following a preferred embodiment of the catalysts of the invention, there is used as the Ru(II) precursor, the compound of formula (COD)Ru(2-methallyl)2 !, the bis(2,4-dimethylpentadienyl)ruthenium (e.g. L. Stahl et al. or T. D. Newbound et al., refs cited) or the bis(2,4-dimethyl-1-oxapenta-dienyl)ruthenium complexes (e.g. T. Schmidt et al., ref. cited).
Among the bidentate phosphines which can be used as ligands in the catalysts of the invention, there can be cited, as preferred embodiments, those selected from the group consisting of the chiral phosphines known under the abbreviations of Me-DuPHOS, Et-DuPHOS, BINAP, To1BINAP, SKEWPHOS, DIPAMP and CHIRAPHOS, the structures of which are represented hereafter for one of the enantiomers in particular: ##STR2##
Other chiral bidentate phosphines which can be used in the chiral catalysts of the invention include for instance those known under the name of NORPHOS, or yet analogues of the DuPHOS type ligands, so-called "BPE", the structures of which are represented hereafter for one of the enantiomers. ##STR3##
Other particularly useful ligands for the preparation of the catalysts of the invention are the chiral diphosphines of formula: ##STR4## in particular that known under the designation of (R)-(S)-JOSIPHOS (R=cyclohexyl, R'=phenyl) or (-)-JOSIPHOS.
Moreover, it has been ascertained that other ligands, chiral or achiral, can be used to prepare the catalysts according to the invention, which catalysts proved capable of catalyzing the hydrogenation of substrates (II) with a cis stereoselectivity above 80% and, in most cases, 95%. To this end, there can be cited the achiral or racemic bidentate ferrocenyl-diphosphines such as represent hereafter: ##STR5##
Other bidentate phosphines useful as ligands are represented below: ##STR6##
More generally, one can use as ligands in the catalysts of the invention any bidentate diphosphine comprising substituent groups capable of rendering said diphosphine sufficiently electron-rich to allow it to stabilize the metal, without however depriving said metal from its ability to coordinate substrate (II).
It has also been observed that the diphosphines having a certain number of alkyl or cycloalkyl type substituents revealed themselves particularly useful for the aim of the invention and provided catalysts which were very active and efficient for the hydrogenation of substrates (II).
It is apparent from the above that the preferred ligands for preparing the catalysts of the invention are diphosphine ligands in which the two phosphorous atoms are bridged by groups of the alkyl, 1,2-benzenyl, bis(naphtalenyl) or yet 1,1'-ferrocenyl type, optionally substituted, said phosphorous atoms further carrying two other substituents, which can be identical or different and formed of alkyl, aryl or alkylaryl radicals, or yet alicyclic radicals.
The catalysts of the invention which comprise diphosphine ligands of the DuPHOS, BINAP, To1BINAP, SKEWPHOS or JOSIPHOS type are particularly advantageous as catalysts for the asymmetric hydrogenation of the substrates of formula (II), as is apparent from the examples presented further on.
Amongst the latter catalysts, those which comprise ligands of the SKEWPHOS, JOSIPHOS or Me-DuPHOS type showed themselves capable of particularly advantageous performances and are therefore preferred according to the invention. (R,R)-(-)-Me-DuPHOS, or (-)-1,2-bis(2,5-dimethylphospholano)benzenyl made it possible to obtain choice catalysts according to the invention.
The ligands of the type L1 to L13 represented below are either commercially available compounds or they can be prepared according to processes analogous to previously described methods.
For example, the ligands of the DuPHOS, SKEWPHOS, BINAP, CHIRAPHOS, DIPAMP and NORPHOS type are mostly commercial products and, in any event, they can be obtained via processes described in the literature, namely in reference works such as the books of R. Noyori, Asymmetric Catalysis in Organic Synthesis, John Wiley & Sons, N.Y (1994), Chap. II and J. Ojima, Catalytic Asymmetric Synthesis, VCH Publishers, N.Y. (1994), Chap. I.
The L13 ligands are very common and commercialized, whereas those which contain ferrocenyl groups are either commercialized (such is the case for example of the compound of structure L10 wherein R represents a phenyl radical), or they can be prepared by methods analogous to those described for example by M. D. Rausch et al., J. Organometallic Chem. 1967, 10, 127, R. A. Brown et al. 1992, 20, 2611 and G. Herberich et al., Chem. Ber. 1995, 128, 689. Moreover, some of these ferrocenyldiphosphine type ligands are novel compounds which are also the object of the invention. Such is the case namely of the ligands of formula (L8) wherein R1 =trimethylsilyl and R2 =isopropyl.
The ligands of the (L11) type wherein R=cyclohexyl et R'=phenyl, known under the designation of JOSIPHOS, can be prepared as is described by A. Togni et al., J. Amer. Chem. Soc. 1994, 116, 4062. They are also commercially available, and the same applies to their analogues (origin: STREM Chemicals, Inc.).
The above-mentioned acids of formula HX, used for the preparation of the catalysts of the invention, are typically used in the form of the corresponding etherates (for example HBF4.R2 O, R═CH3 or C2 H5) or of any other onium type salt (phosphonium or sulfonium, for example). These etherates are commercial products, or they can be prepared from the corresponding silver salts, by reacting with HCl. In the latter case, the silver salt, for example AgBF4, AgPF6, AgSbF6 or AgAsF6 will be typically reacted with HCl, in a solvent containing a dialkylether, for example a mixture of dichloromethane and diethylether. As the silver chloride precipitates, it provides the etherate solution of the acid, with is then used according to the invention in the reaction with the ruthenium complex and the phosphine ligand.
Thus, as the HX acid, one can cite an acid selected from the group consisting of HBF4, HPF6, HSbF6, HAsF6, and HB 3,5-(CF3)2 C6 H4 !4. All these acids have as common characteristic the fact that their anion is non-coordinating.
According to a preferred embodiment of the catalyst of the invention, there is used tetrafluoroboric acid etherate.
The reaction which characterizes the process for the preparation of the invention's catalysts takes place in a non-coordinating or weakly coordinating medium, under inert atmosphere. By the latter, one means here an atmosphere whose oxygen content is lower than 200 ppm and, preferably, not above 5 to 10 ppm.
By non-coordinating or weakly coordinating medium, it is meant here for example, a non-coordinating or weakly coordinating solvent. It may also be meant moreover that the reaction occurs in a solvent as defined above, but also in the presence of the above-cited substrate of formula ##STR7## wherein R1 represents a linear or branched C1 to C4 alkyl radical and R2 represents a saturated or unsaturated, linear or branched, C1 to C8 hydrocarbon radical.
It has yet been ascertained that useful catalysts could also be obtained in the absence of the solvent, i.e. in the presence of the substrate of formula (II) alone. We observed that, surprisingly, the presence of said substrate also allowed the formation of Ru(II) dicationic species which were themselves capable of catalyzing the hydrogenation of the above-mentioned products (II) under the conditions which are the object of the present invention and which will be described in detail hereafter.
When the treatment of the Ru(II) complex and the diphosphine ligand, which may be a chiral one, with the HX-acid is carried out in a solvent, the latter will be preferably selected from the group consisting of dichloromethane, dichloroethane, ethyl pivalate, methyl acetate, ethyl acetate, isopropyl acetate, acetone, 2-butanone, 3-pentanone and any mixture of two or several of these solvents.
According to a preferred embodiment, dichloromethane or a mixture of the latter with other, non-coordinating or weakly coordinating solvents, in particular those mentioned above, is used.
It should be pointed out that the use of the coordinating solvents which are typically employed in the preparation of the prior art catalysts did not make it possible to obtain catalysts which, in the course of their application in the hydrogenation of the appropriate substrate (II), are capable of providing essentially the above-mentioned preferred isomer of Hedione®, as is clearly evident from the examples given below. This, unlike what we could observe with the catalysts of the present invention.
Now, the structure of the dicationic complexes of Ru(II) according to the present invention is not known. Without wanting to prejudge their exact structural nature, it seems nevertheless quite probable that they obey a formula of the type (diene)Ru(P*--P*)S2 !2+ (anion-)2, wherein the ligand S represents the solvent (for example CH2 Cl2 and/or ether), the substrate or a mixture of both, and P*--P* represents a bidentate phosphine ligand, which may be chiral. In fact, given the weak electron-donor character of the solvent and/or of substrate (II), and considering what is known from the prior art, it is totally surprising to observe the formation and any hydrogenation activity of these catalysts, when the coordination structure around the metal cannot be entirely defined on the basis of the general knowledge in the art, by analogy to the catalysts which have been prepared according to the known methods.
These new catalysts proved of excellent efficiency there where the catalysts which had been prepared according to the methods described in the prior art failed. We found, in fact, that their use for the hydrogenation, as the case may be asymmetric, of the compounds of formula (II) made it possible to obtain isomers of the compounds of formula ##STR8## in which R1 and R2 have the meaning indicated above, essentially in a cis configuration and, optionally, in an enantioselective manner, as a function of the chirality of the catalyst, and with excellent optical purity.
More particularly, we were able to obtain methyl (+)-(1R)-cis-3-oxo-2-pentyl-1-cyclopentaneacetate with a cis purity above 98% and an enantiomeric excess of at least 60%.
Among these catalysts, and as is apparent from the examples presented further on, those which were obtained starting from the complex of formula (COD)Ru(2-methallyl)2 ! and the (-)-Me-DuPHOS or (-)-JOSIPHOS ligand, using HBF4 -etherate in a medium of dichloromethane, or its mixtures with methyl 3-oxo-2-pentyl-1-cyclopentene-1-acetate, proved to be particularly advantageous for the preparation of (+)-cis-Hedione®.
The catalysts comprising the chiral ligands previously cited proved to be particularly useful for the preparation of optically active compounds of formula (I), in particular of methyl (+)-(1R)-cis-3-oxo-2-pentyl-1-cyclopentaneacetate.
Of course, the use of the enantiomers of the above-cited ligands enables the preparation of the (-)-(1S)-configuration enantiomer of methyl cis-3-oxo-2-pentyl-1-cyclopentane-acetate, as the optical configuration of the catalyst determines that of the hydrogenation product of substrate (II).
According to the invention, the preparation of the catalyst can take place at room temperature or a lower temperature. Moreover, the temperature of the above-mentioned treatment does not seem to be a critical parameter of the process, susceptible of affecting the catalyst's properties and its efficiency in the hydrogenation of the substrates (II). The application of room temperature is of course advantageous from a practical point of view.
On the other hand, we observed that the ratio between the molecular weight of the HX acid, for example HBF4, HPF6, HSbF6 ou HAsF6, and the molecular weight of the ruthenium complex is a critical parameter which determines the catalyst's characteristics and its efficiency in the asymmetrical hydrogenation of the above-mentioned substrates according to the present invention, and more particularly of methyl 3-oxo-2-pentyl-1-cyclopentene-1-acetate. This is all the more surprising in that the prior art is totally silent on this subject. Actually, known studies often report the use of a substantial excess of acid, relative to the amount required to form the cationic ruthenium complex in the presence of the bidentate phosphine ligand.
Now, we have ascertained that the use of an excess of acid renders the catalysts inactive or inefficient in the context of the present invention. As is apparent from the examples below, it may even prove to be advantageous to use the acid in a ratio which is inferior to the stoechiometric amount. Thus the acid will be preferably used in a ratio from 1.5 to 2 mole equivalents, per mole of the Ru(II) complex. More preferably, the ratio between these two reagents will be about 2 mole equivalents of acid per mole of complex.
Likewise, the equimolar ratio between the appropriate Ru(II) complex and the bidentate diphosphine also seems a critical parameter of the invention.
The invention also concerns a process for the preparation of Ru(II) catalysts, characterized in that equimolar amounts of an appropriate Ru(II) complex and a bidentate diphosphine ligand are reacted, under an inert atmosphere and in a non-coordinating or weakly coordinating medium, with an acid of formula HX, wherein X is a non-coordinating anion, the acid being employed in a ratio which does not exceed 2 molar equivalents per mole of Ru(II) complex.
As previously mentioned, the appropriate Ru(II) complexes, and in particular the preferred complex (COD)Ru(2-methylallyl)2 !, which are used as starting products in the process for the preparation of the catalysts according to the present invention, are typically known compounds which can be prepared as is described in the above-cited prior art documents, or by processes which are analogous to those known.
On the other hand, the phosphines which form the ligands of the catalyts according to the present invention, and which determine their chirality, are either commercially available compounds or can be prepared by known methods.
As cited above, the preparation of the catalyst can be executed in a medium which is constituted by a solvent or a mixture of the solvent with the substrate (II). This last embodiment, as well as that according to which the catalyst is prepared in the presence of only the substrate (II), are methods particularly suitable for the in situ preparation of the catalysts, in the medium of the hydrogenation reaction, described further on.
The catalysts according to the present invention thus prepared are obtained as solutions in the solvent and/or the substrate (II) of the product which is the result of the reaction of the Ru(II) complex with the diphosphine ligand and the HX acid. These catalytic solutions may be used as such for the asymmetric hydrogenation of substrates (II). They can be kept under an inert atmosphere and will stay active for several days. Moreover, they may also be concentrated under vacuo to give the catalysts in a solid form.
The catalysts can also be generated in situ in the hydrogenation medium, as will become apparent below.
In this process, the order in which the reagents are mixed does not seem to have a critical impact on the properties of the resulting catalysts. Thus, we found that it was possible to first mix the Ru(II) precursor, for example (COD)Ru(2-methallyl)2 !, with the diphosphine ligand, in particular (-)-Me-DuPHOS, in a solvent, typically dichloromethane, and add thereafter to this mixture the selected acid, for example HBF4 (in the form of its etherate), optionally dissolved in dichloromethane. Catalytic solutions according to the present invention are thus obtained, having a variable concentration in the catalyst according to the present invention, for example of the order of 0.01M (0.01 moles of catalyst/1 of catalytic solution), which proved to be very advantageous in the hydrogenation of substrates (II).
Alternatively, very good catalysts were also obtained by first mixing the diphosphine ligand, in particular (-)-Me-DuPHOS, with the acid of formula HX, in the form of an etherate or an onium salt, in particular HBF4 -etherate, for example in dichloromethane. The product thus obtained may be reduced to the form of a solid onium salt by removing under vacuo the ether and CH2 Cl2, and thereafter be used in the reaction with the Ru(II) complex in a solvent to give the desired catalysts. This embodiment is quite useful in practice, as it allows separate preparation of the salts of the ligands, which thereafter can react with the Ru(II) complex.
The dicationic compounds of Ru(II) according to the invention prove to be very useful as catalysts in hydrogenation reactions. In particular, they show an excellent efficiency in the conversion of substrates (II), and the invention therefore also concerns a process for the preparation of a compound of formula ##STR9## in which R1 represents a linear or branched alkyl radical from C1 to C4 and R2 represents a saturated or unsaturated hydrocarbon rest, linear or branched, from C1 to C8, essentially in the form of an isomer of cis configuration, characterized in that a substrate of formula ##STR10## in which R1 and R2 have the meaning indicated above, is catalytically hydrogenated in the presence of a Ru(II) catalyst according to the present invention as previously described, and at a hydrogen pressure of from 10 to 100 bar (2 to 10×106 Pa).
According to a preferred embodiment of the invention, the catalyst is generated in situ before the hydrogenation of substrate (II) or, optionally, in the presence of the latter, by treating equimolar amounts of the Ru(II) complex, in particular the compound of formula (COD)Ru(2-methylallyl)2 !, and an appropriate chiral bidentate phosphine ligand, selected, for example, from the group consisting of the diphosphines which are known under the abbreviations of Me-DuPHOS, Et-DuPHOS, BINAP, To1BINAP, SKEWPHOS, DIPAMP, CHIRAPHOS and JOSIPHOS, with the etherate of tetrafluoroboric acid in a proportion of about 2 molar equivalents of HBF4 per mole of Ru(II) complex. This preferred embodiment enables the preparation of the above-mentioned compound (I) in the form of an optically active isomer of (1R)-cis configuration.
All the racemic or achiral ligands mentioned above provide catalysts which make it possible to obtain the compounds (I) in the form of the racemic cis-isomer. Of course, in the case of racemic ligands (for example L8 and L9), their corresponding enantiomers can be obtained by separation of the racemic ligand, and these enantiomers of the ligand may thereafter serve to prepare optically active catalysts according to the invention.
When the preparation of the catalyst takes place in the absence of substrate (II), it is preferred to first prepare the mixture of the Ru(II) complex and the diphosphine ligand, as a solution in a non-coordinating or weakly coordinating solvent, and to add to this solution the acid comprising the non-coordinating ion, in particular the etherate of tetrafluoroboric acid, generally in the same solvent or in another solvent with the same characteristics. The catalytic solution thus obtained will then be used in the hydrogenation of substrate (II).
When a hydrogenation medium which comprises a solvent is used, preferably the same solvent as that in which the catalyst has been obtained is used. For this purpose, one can use a chlorinated hydrocarbon like dichloromethane, dichlororethane or a mixture of both. The use of dichloromethane, optionally in a mixture with the other solvents which have been cited above, has proved to be very advantageous according to the invention.
According to a particularly preferred embodiment of the process according to the present invention, methyl 3-oxo-2-pentyl-1-cyclopentene-1-acetate is used as a substrate in order to obtain Hedione® in the form of the preferred (+)-cis-configuration isomer.
The catalysts according to the present invention which have ligands of the DuPHOS type, and in particular Me-DuPHOS, have proved to be particularly useful for the hydrogenation of this substrate.
The hydrogenation which characterizes the process according to the invention is carried out under a hydrogen pressure which can vary from 10 to 100 bar (2 to 10×106 Pa). Pressures from 70 to 100 bar, in particular from 90 to 100 bar, are preferred.
The reaction may take place at temperatures of up to 50° to 60° C., or even 100° C. Preferably, one will work at room temperature or a lower temperature. It has been found that temperatures of down to -10° C., or even lower, made it possible to obtain very useful results.
The molar concentrations of the Ru(II) catalyst with respect to the substrate typically vary from 0.01 to 4 mole %, preferably from 0.1 to 2 mole %. According to a more preferred embodiment, they shall be of the order of 0.3 or 0.4 mole %.
Moreover, it has also been found that it is advisable to use solutions in which the substrate is concentrated, better results having been obtained when the concentration of the substrate in the hydrogenation medium was from about 0.4 to 1.5 molar, relative to the volume of said medium.
It is also possible to add a trialkylamine, preferably diisopropylethylamine (DIPEA), to this medium. It has in fact been observed that, under certain conditions, the hydrogenations carried out in the presence of the latter provided more useful results. The concentration in which this base may be added to the reaction medium varies in a molar ratio of from 0.1:1 to 0.5:1, relative to the Ru(II) catalyst. The best yields of final product were obtained when diisopropylamine was added in a proportion of 0.2 equivalents with respect to the catalyst.
According to a particular embodiment of the hydrogenation process according to the invention, in which the catalyst is formed in situ in the hydrogenation medium, the substrate which is to be hydrogenated is first mixed with the equimolar mixture of (COD)Ru(2-methylallyl)2 ! and diphoshine ligand, optionally in a solvent, and thereafter HBF4 -etherate or another salt of a HX acid is added to the thus obtained solution, in the proportion mentioned above. The thus obtained reaction medium is thereafter pressurized under hydrogen in a conventional manner, as will be described in the examples below. This etherate or another salt of the onium type can be added as such or in the form of a solution, and either in the same solvent as that previously used, or in a different solvent.
The invention thus provides new catalysts and processes for the use of these catalysts which allow the preparation, in a single step, and under conditions which are advantageous and susceptible of industrial application, of products useful in perfumery, in a stereoselective manner and, as the case may be, enantioselective, and in excellent yields. Unlike the prior art catalysts, the catalysts of the present invention are capable of hydrogenating substrates (II) with very fast reaction speeds, substrate conversion rates above 98% and providing essentially the diastereomer of (1R)-cis configuration of the desired compounds.
The invention will now be described in greater detail by means of the following examples, in which the temperatures are indicated in degrees centigrade (°C.) and the abbreviations have the meaning generally recognized in the art.
EMBODIMENTS OF THE INVENTION EXAMPLE 1
Preparation of the catalysts
General Method
In a glove box under argon, at room temperature, a Schlenk tube was charged with equimolar amounts of (COD)Ru(2-methylallyl)2 ! or another complex of Ru, and the selected ligand. The dried and degassed solvent necessary to dilute this mixture was added. After 5 minutes, tetrafluoroboric acid etherate (or another onium salt), optionally in solution in the non-coordinating solvent, was added dropwise using a syringe, while the mixture was stirred using a Teflon® covered magnetic stirring rod. After stirring, a small amount of solvent was further added and stirring was maintained for about half an hour. The catalyst thus obtained in the form of a solution can be stored for several days in the glove box without losing its activity.
The solution may also be concentrated under vacuo to provide the catalyst in a solid form.
In a typical run, 0.20 mmole (64 mg) of (COD)Ru(2-methylallyl)2 ! (origin: Acros Organics) and 0.20 mmole (61 mg) of (-)-(R,R)-Me-DuPHOS or (-)-1,2-bis-(2R,5R)-2,5-dimethylphospholano)-benzene; origin: Strem Chemicals! were reacted in 4 ml of CH2 Cl2. A 0.10N solution (4 ml) of HBF4.Et2 O (Et=ethyl; 0.40 mmole) in CH2 Cl2 was added. After stirring for 30 min, another 8 ml of CH2 Cl2 were added, and stirring was continued for half an hour. The catalyst thus obtained was used as such in the hydrogenation reactions.
Optically active catalysts were thus prepared with the following ligands: (+)-(S,S)-Me-DuPHOS; (-)-(R,R)-Me-DuPHOS; (+)-(S,S)-Et-DuPHOS; (-)-(R,R)-Et-DuPHOS; (+)-(R)-BINAP; (-)-(S)-BINAP; (-)-(R,R)-NORPHOS; (-)-(S,S)-CHIRAPHOS; (+)-(R,R)-CHIRAPHOS; (-)-(S,S)-SKEWPHOS; (+)-(R,R)-SKEWPHOS; (-)-(R,R)-DIPAMP; (+)-(S,S)-DIPAMP; (-)-(S)-To1BINAP; (+)-(R)-To1BINAP; (-)-(R)-(S)-JOSIPHOS et (+)-(S)-(R)-JOSIPHOS. All of these ligands are commercially available or are prepared according to known methods.
Other catalysts which were prepared according to the method described above comprised ligands of the type L7 (R=methyl, ethyl or isopropyl), L8 R1 =(CH3)3 Si and R2 =phenyl or isopropyl!, L9 (R1 =CH3 and R2 =phenyl), L10 (R=ethyl, isopropyl or phenyl), L11 (R=cyclohexyl and R'=phenyl), L12 (R=phenyl) and L13 (n=1, 2, 3 or 4).
The ligands L13 mentioned above are commercially available (origin: Fluka Chemie and Aldrich), as is the ligand of type L12 cited above (origin: Strem Chemicals). The above mentioned ligands of the L8, L9 and L10 type were prepared according to known methods (see references cited above and I. R. Butter et al., Synth. React. Inorg. Met. -Org. Chem. 1985, 15, 109) from ferrocene and according to the following reaction schemes: ##STR11##
For the preparation of the ligands of type L7, one can use, for example, the method described in U.S. Pat. No. 5,171,892.
In the method of preparation of the catalyst described above, a solution of HBF4.Et2 O in diethyl ether (0.2M) was also used, giving similar results.
EXAMPLE 2
Hydrogenation of methyl 3-oxo-2-pentyl-1-cyclopentene-1-acetate
General method of hydrogenation
In a glove box under argon and at room temperature, a glass beaker adapted for use in an autoclave was charged with the catalyst solution obtained as described in example 1, the above-mentioned substrate which had been prior degassed, and the degassed solvent. The beaker containing a stirring rod was introduced in the autoclave inside the glove box, and the autoclave was sealed before being taken out of the glove box to be pressurized. The inlets of the autoclave were purged with H2 and thereafter pressurized to the chosen value. The reaction was allowed to occur at room temperature. The pressure was released under air, the autoclave was opened and the solution concentrated under reduced pressure. The catalyst was precipitated with pentane, filtered and the filtrate was concentrated to provide the desired Hedione®. The product can be purified by distillation in a bulb-to-bulb apparatus (150°-200° C./5 Pa) without changing the diastereomeric ratio.
In a typical run, for example, there was used a H2 -pressure of 90 bar (9×106 Pa), room temperature and a reaction time of 1.5 h for a substrate weight of 269 mg (1.20 mmole) and 1 ml of CH2 Cl2, the catalyst being present at a ratio of 1 mole % relative to the substrate (1.0 ml of a solution of the (-)-(R,R)-Me-DuPHOS catalyst specifically described in example 1).
Table I below gives a summary of the results of the different runs which were carried out under various conditions and with catalysts which had been prepared as described in example 1, by means of the chiral ligands indicated in table I.
Replacing the ligands mentioned in this table by their respective enantiomers enabled the preparation of products in which the cis/trans ratio was identical to the value indicated in the table for the enantiomer in question, but wherein the ratio (+)-(cis)/(-)-cis and (-)-trans/(+)-trans was the reverse of that indicated in the table.
An analysis of this table shows that when using coordinating solvents such as methanol (runs 1 and 2) or yet mixtures of coordinating and non-coordinating solvents, either a bad yield in Hedione® or an unfavorable cis/trans ratio is obtained, in comparison with those runs which were carried out in, for example, dichloromethane. Moreover, when the substrate is too diluted (run 7), no hydrogenation is observed.
                                  TABLE I
__________________________________________________________________________
                                                          Enantio-
              Catalyst
                   Substrate              Yield     Enantio-
                                                          meric
              concentra-
                   concentra-
                        Reaction
                             Solvent and
                                     H.sub.2
                                          of    Isomer
                                                    meric ratio
              tion tion time other   pressure
                                          Hedione ®
                                                ratio
                                                    ratio (-)trans/
Run
   Ligand     (mole %)
                   (M)  (h)  conditions
                                     (10.sup.6 Pa)
                                          %     cis/trans
                                                    (+)cis/(-)cis
                                                          (+)trans
__________________________________________________________________________
1  (-)-Me-DuPHOS
              2    0.45 96   MeOH/THF (3/1)
                                     9    55    9:91
                                                    80:20 80:20
2  (-)-Et-DuPHOS
              2    0.45 96   MeOH/THF (3/1)
                                     9    88    7:93
                                                    77:23 77:23
3  (-)-Me-DuPHOS
              2    0.53 0.5  CH.sub.2 Cl.sub.2
                                     9    99    97:3
                                                    80:20 61:39
4  (-)-Me-DuPHOS
              1    0.53 1.5  CH.sub.2 Cl.sub.2
                                     9    99    98:2
                                                    80:20 60:40
5  (-)-Me-DuPHOS
              1    0.53 16.5 T = -10° C.
                                     9    99    98:2
                                                    86:14 60:40
                             CH.sub.2 Cl.sub.2
6  (-)-Me-DuPHOS
              1    0.53 3.25 CH.sub.2 Cl.sub.2
                                     4.5  80    98:2
                                                    80:20 53:47
7  (-)-Me-DuPHOS
              1    0.04 68   CH.sub.2 Cl.sub.2
                                     9    6.5   60:40
                                                    68:32 51:49
8  (-)-Me-DuPHOS
              0.5  0.79 5    CH.sub.2 Cl.sub.2
                                     9    99    98:2
                                                    80:20 58:42
9  (-)-Me-DuPHOS
              0.25 1.18 16   CH.sub.2 Cl.sub.2
                                     9    99    96:4
                                                    80:2()
                                                          67:33
10 (-)-Me-DuPHOS
              2    0.37 15   toluene-CH.sub.2 Cl.sub.2
                                     9    4.5   45:55
                                                    --    --
                             (1:2)
11 (+)-(R,R)-SKEWPHOS
              2    0.53 3    CH.sub.2 Cl.sub.2
                                     10   24    95:5
                                                    75:25 58:42
12 (-)-(S,S)-CHIRAPHOS
              2    0.53 2    CH.sub.2 Cl.sub.2
                                     9    97    96:4
                                                    31:69 --
13 (-)-(R,R)-NORPHOS
              2    0.53 2    CH.sub.2 Cl.sub.2
                                     9    98    96:4
                                                    57:43 --
14 (+)-(S,S)-DIPAMP
              2    0.53 2    CH.sub.2 Cl.sub.2
                                     9    50    94:6
                                                    69:31 --
15 L7 (R = CH.sub.3)
              2    0.53 12   CH.sub.2 Cl.sub.2
                                     5    98    97:3
                                                    67:33 --
16 L7 (R = C.sub.2 H.sub.5)
              2    0.53 12   CH.sub.2 Cl.sub.2
                                     5    89    98:2
                                                    73:27 --
17 L7 (R = isopropyl)
              2    0.53 12   CH.sub.2 Cl.sub.2
                                     5    97    97:3
                                                    73:27 --
18 LII (R = cyclohexyl
              2    0.50 4.5  CH.sub.2 Cl.sub.2
                                     9    98    98:2
                                                    77:23 --
   R' = phenyl))
__________________________________________________________________________
EXAMPLE 3
The substrate mentioned in example 2 was hydrogenated according to a method analogous to that described above, by proceeding as follows.
In a glove box under argon and at room temperature, (COD)Ru(2-methylallyl)2 ! (16.5 mg; 0.051 mmole) was dissolved in dichloromethane (1 ml) and stirred for 2 min. To the resulting solution, a solution of (+)-R-BINAP (+)-(R)-2,2'-bis (diphenylphosphino-1,1'-binaphtalene); 31.6 mg; 0.051 mmole; origin: Fluka Chemicals! in dichloromethane (2 ml) was added and stirred for about 30 min. Then tetrafluoroboric acid etherate (14 μl; origin: Fluka Chemie) was added. Having stirred for 30 min, a solution of methyl 3-oxo-2-pentyl-1-cyclopenteneacetate (0.5 g; 2.23 mmole) in dichloromethane (10 ml) was added and stirred for 30 min at room temperature. This solution, still under Ar, was charged in an autoclave which contained a glass beaker with a magnetic stirrer. After purging with H2, the autoclave was pressurized at 9×106 Pa for 64 h at 20° C. After decompressing the orange solution was taken and concentrated under high vacuo. The residue was taken in pentane (2 ml) to precipitate the catalyst. The solution was filtered on a 0.45 μm acrodisc and concentrated. 500 mg of a transparent oil containing 93% Hedione®, with a cis/trans ratio of 72:28, and 6% of starting product were thus obtained. The enantiomeric ratios were as follows: (+)-cis/(-)-cis=73/27; (+)-(trans)/(-)-trans=35/65.
EXAMPLE 4
In a glove box under argon and at room temperature, 5.376 g (24 mmole) of the substrate cited in the above examples, 19.2 mg of (COD)Ru(2-methylallyl)2 ! (0.06 mmole), 0.06 mmole (18.4 mg) of (-)-Me-DuPHOS and 12 ml of CH2 Cl2 were charged into a glass beaker adapted for use in an autoclave and equipped with a stirrer. Thereafter, 0.12 mmole of HBF4 etherate (1.2 ml of a 0.1N solution in dichloromethane) were added. After stirring for 1 h, the beaker containing a stirring rod was introduced in the autoclave inside the glove box, and the autoclave was closed before being pressurized outside the glove box. The inlets of the autoclave were purged with H2 and thereafter pressurized at 2×106 Pa. The reaction was allowed to proceed at room temperature for 17 h. The autoclave was degassed and opened and the solution concentrated under reduced pressure. The catalyst was precipitated with pentane, filtered and the resulting filtrate concentrated to obtain the desired Hedione®. The product thus obtained (yield 99%) showed the following isomer ratios: cis/trans=97/3 ; (+)-cis/(-)-cis=80/20.
EXAMPLE 5
The reaction was carried out in a similar manner to that described in examples 2 to 4, but 2.2 equivalents of tetrafluoroboric acid (from a 0.2M solution. of HBF4 etherate in diethyl ether) per mole of Ru(II) complex were used in the preparation of the catalyst which was carried out analogously to the way described in example 1.
Moreover, in the runs which are summarized in the tables below, the catalyst was used in solid form. Thus, methyl 3-oxo-2-pentyl-1-cyclopentene-1-acetate (0.5 mmole in 2 ml of CH2 Cl2) was hydrogenated in the presence of the amount of solid catalyst indicated in the tables.
Table II below summarizes the results which were obtained in the hydrogenation reactions carried out with different catalysts (variation of the nature of the ligand) in the concentrations indicated, a hydrogen pressure of about 100 bar (10×106 Pa), room temperature and a reaction time of about 22 h.
Table III summarizes the results which were obtained with different catalysts (variation of the nature of the ligand) and by varying several reaction parameters. All reactions were carried out at room temperature, unless otherwise indicated.
                                  TABLE II
__________________________________________________________________________
                          Yield
           Catalyst       of    Isomer
                                    Enantiomeric
                                          Enantiomeric
           concentration  Hedione ®
                                ratio
                                    ratio ratio
Run
   Ligand  (mole %)
                  Solvent %     cis/trans
                                    (+)cis/(-)cis
                                          (-)trans/(+)trans
__________________________________________________________________________
1  (-)-Me-DuPHOS
           2      MeOH    31    32:68
                                    80:20 78:22
2  (-)-Me-DUPHOS
           2      MeOH +  9.1   72:28
                                    65:35 54:46
                  triethylamine*
3  (-)-Me-DUPHOS
           2      triethylamine** +
                          4.5   68:32
                                    55:45 41:59
                  MeOH
4  (-)-Me-DuPHOS
           2      THF     5.5   61:39
                                    63:37 56:44
5  (-)-Me-DuPHOS
           2      CH.sub.2 Cl.sub.2
                          100   82:18
                                    80:20 77:23
6  (-)-Et-DuPHOS
           1      CH.sub.2 Cl.sub.2
                          77    80:20
                                    70:30 73:27
7  (+)-BINAP
           1      CH.sub.2 Cl.sub.2
                          77    74:26
                                    71:29 65:35
8  (-)-Me-DUPHOS
           1      CH.sub.2 Cl.sub.2
                          91    79:21
                                    79:21 77:23
__________________________________________________________________________
 *1 equivalent per mole of catalyst
 **2 equivalents per mole of catalyst

                                  TABLE III
__________________________________________________________________________
            Catalyst              Yield Iso-
            concentra-
                 Reaction     H.sub.2
                                  of    meric
                                            Enantiomeric
                                                  Enantiomeric
            tion time         pressure
                                  Hedione ®
                                        ratio
                                            ratio ratio
Run
   Ligand   (mole %)
                 (h)  Solvent (10.sup.6 Pa)
                                  %     cis/trans
                                            (+)cis/(-)cis
                                                  (-)trans/(+)trans
__________________________________________________________________________
1  (-)-Me-DuPHOS
            1.0  14.5 CH.sub.2 Cl.sub.2
                              10  93    94:6
                                            80:20 72:28
2* (-)-Me-DUPHOS
            4.0  6.0  CH.sub.2 Cl.sub.2
                              9   90    86:14
                                            83:17 79:21
3  (-)-Me-DuPHOS
            1.0  40.0 CH.sub.2 Cl.sub.2
                              10  95    75:25
                                            79:21 77:23
4  (-)-Me-DuPHOS
            1.0  40   CH.sub.2 Cl.sub.2 +
                              10  95    82:18
                                            79:21 76:24
                      DIPEA.sup.a) (0.2 eq.)
5  (-)-Me-DuPHOS
            2.0  2    CH.sub.2 Cl.sub.2+
                              9   43    96:4
                                            80:20 56:44
                      DIPEA.sup.a) (1.0 eq.)
6  (-)-Me-DuPHOS
            2.0  2    CH.sub.2 Cl.sub.2 +
                              9   2,1   59:41
                                            46:54 60:40
                      DIPEA.sup.a) (2.0 eq.)
7**
   (-)-Me-DuPHOS
            2.0  2    CH.sub.2 Cl.sub.2 +
                              9   98    97:3
                                            81:19 64:36
                      DIPEA.sup.a) (0.2 eq.)
8  (-)-(R,R)-DIPAMP
            2.0  2    CH.sub.2 Cl.sub.2 +
                              9   50    94:6
                                            31:69 52:48
                      DIPEA.sup.a) (0.2 eq.)
9  (-)-(S)-TolBINAP
            2.0  2    CH.sub.2 Cl.sub.2 +
                              8   88    96:4
                                            31:69 48:52
                      DIPEA.sup.a) (0.2 eq.)
__________________________________________________________________________
 .sup.a) diisopropylethylamine
 *Temperature 0-5° C.
 **Substrate degassed before hydrogenation
EXAMPLE 6
In a glove box under argon and at room temperature, 38 mg of (COD)Ru(2-methylallyl)2 ! (0.12 mmole) and 36 mg (0.12 mmole) of (-)-Me-DuPHOS were dissolved in 5.38 g (24 mmole) of methyl-3-oxo-2-pentyl-1-cyclopentene-acetate in a glass beaker adapted for use in an autoclave which was equipped with a stirrer. Thereafter, 39 mg of HBF4 etherate (0.24 mmole; 32.7 μl, syringe) were gently added under stirring. After stirring for 4 h, 3.4 ml of this catalytic solution (containing about 0.075 mmole of catalyst) were transferred to another beaker, and another 8.38 g (37.4 mmole) of methyl 3-oxo-2-pentyl-1-cyclopentene-1-acetate (total amount about 53 mmole) were added to this. Working as previously described, the substrate was hydrogenated at a H2 pressure of 5×106 Pa. The reaction was allowed to proceed for 20 h at room temperature. The autoclave was degassed, opened, and the catalyst was precipitated using pentane, filtered and the filtrate concentrated to obtain the desired Hedione®. The thus obtained product (yield 99% based on the above mentioned substrate) showed the following isomer ratios: cis/trans=97/3: (+)-cis/(-)-cis=80/20, 60% e.e.
By working under similar conditions but varying the nature of the solvent used in the hydrogenation, i.e. of the solvent of the mixture of (COD)Ru(2-methallyl)2 ! and (-)-Me-DuPHOS, as well as that of the solvent of the tetrafluoroboric acid etherate, the results given in the table below were obtained. The hydrogenated substrate (II) was always methyl 3-oxo-2-pentyl-1-cyclopentene-1-acetate, and the catalyst concentration was about 2 mole % relative to the mentioned substrate, unless otherwise indicated.
When the tetrafluoroboric acid etherate is used in solution, its concentration in the solution is always about 0.1M (moles/1).
Yields of the order of 99% in Hedione®, based on starting substrate (II) present in the hydrogenation medium, were systematically obtained. Of course, when ratios of catalyst/substrate of the order of 0.5 mole % or less were used, prolonged reaction times (in the range from 6 to 20 h) were necessary to obtain a complete and quantitative conversion of the substrate, while hydrogenation times of 1 to 3 h in general were sufficient to obtain this result when the catalyst was present in concentrations of the order of 1 mole % or more, with respect to the substrate.
Every time, almost no losses were observed, only traces of residues (˜1%) being obtained when the hydrogenation product was distilled in a bulb to bulb apparatus or a Leybold distillation apparatus ("thin-film distillation").
                                  TABLE IV
__________________________________________________________________________
                        Isomer
                              Enantiomer
   Hydrogenation
             Solvent for
                        ratio ratio
Run
   solvent   HBF.sub.4.Et.sub.2 O
                        cis/trans
                              (+)-cis/(-)-cis
__________________________________________________________________________
1  dichloroethane
             dichloroethane
                        99:1  70:30
2  methyl pivalate
             dichloromethane
                        98.9:1.1
                              76:24
3  ethyl acetate
             dichloromethane
                        99.3:0.7
                              73:27
4  isopropyl acetate
             dichloromethane
                        99.3:0.7
                              72:28
5  2-butanone
             dichloromethane
                        98.9:1.1
                              79:21
6  methyl acetate
             methyl acetate
                        98.5:1.5
                              75:25
7  methyl acetate
             methyl     99.3:0.7
                              74:26
             acetate/dichloromethane
8  methyl acetate
             dichloromethane
                        99:1  77:23
9  methyl acetate/DHH*
             methyl acetate
                        98.5:1.5
                              75:25
10 acetone   dichloromethane
                        99.5:0.5
                              79:21
11 DHH*      methyl acetate
                        98.2:1.8
                              81:19
12 DHH*      --         98.2:1.8
                              81:19
13 3-pentanone
             dichloromethane
                        98.9:1.1
                              79:21
14 tetrahydrofurane
             dichloromethane
                        no hydrogenation observed
15 toluene   dichloromethane
                        no hydrogenation observed
16 N-methylformamide
             dichloromethane
                        no hydrogenation observed
17 N,N-dimethyl-
             dichloromethane
                        no hydrogenation observed
   formamide
18 sulfuric ether
             dichloromethane
                        very slow reaction
19 chloroform
             chloroform no hydrogenation observed
20 methyl-2-methyl-
             dichloromethane
                        very slow reaction
   proponoate
21**
   DHH*      --         96.7:3.3
                              80:20
__________________________________________________________________________
 *methyl 3oxo-2-pentyl-1-cyclopentene-1-acetate
 **catalyst concentration 0.15 mole %
EXAMPLE 7
The reaction was carried out analogously to that described in example 6, but using 100 g (446 mmole) of methyl 3-oxo-2-pentyl-1-cyclopentene-acetate, 427 mg (1.34 mmole) of (COD)Ru(2-methylallyl)2 !, 410 mg (1.34 mmole) of (-)-Me-DuPHOS and 26.5 ml of HBF4.O(C2 H5)2 in dichloromethane (0.1M, 2.68 mmole). This corresponds to a catalyst concentration of 0.3 mole %, relative to the substrate. 170 ml of dichloromethane were added, and the mixture was hydrogenated at a temperature of 7.5° C. and a pressure of 5×106 Pa for 70 h to obtain methyl (+)-(1R)-cis-3-oxo-2-pentyl-1-cyclopentaneacetate in 99% yield, cis/trans ratio=99.2/0.8 and (+)-cis/(-)-cis ratio=84/16.
EXAMPLE 8
The catalysts according to the invention were prepared using (-)-Me-DuPHOS as ligand and varying on the nature of the acid of formula HX.
The respective acids HBF4, HPF6, HSbF6 and HAsF6 (as etherates) were prepared by reacting 0.2 mmole of the corresponding silver salt in 0.8 ml of dichloromethane, using 0.2 ml of a 1M anhydrous solution of HCl 1M in ether.
The silver chloride formed precipitated immediately, and 1 ml of a 0.2M solution of the respective acid, i.e. HBF4, HPF6, HSbF6 or HAsF6, was obtained.
Thereafter, 6.4 mg of (COD)Ru(2-methylallyl)2 ! (0.02 mmole), 6.4 mg of (-)-Me-DuPHOS (0.021 mmole) and 0.224 g of methyl 3-oxo-2-pentyl-1-cyclopenteneacetate in 2 ml of dichloromethane were charged into a reactor. The solution thus obtained was treated with 0.20 or 0.16 ml (2 or 1.6 molar equivalents of ruthenium complex) of the above-mentioned acid solution.
The mixture was thereafter hydrogenated at room temperature and 10×106 Pa to give the results summarized in the table below. It should be noticed that the runs were not optimized, which explains the poor results obtained in some cases.
__________________________________________________________________________
                                      (-)-Trans/
       Acid  Reaction time
                    Yield of
                          Cis/trans
                               (+)-Cis/(-)-cis
                                      (+)-trans
Run
   Acid
       equivalents
             (h)    Hedione ®
                          ratio
                               ratio  ratio
__________________________________________________________________________
1  HBF.sub.4
       2     3      99.4  88:12
                               81:19  79:21
2  HBF.sub.4
       1.6   3      98.7  87:13
                               82:18  81:19
3  HAsF.sub.6
       2     3.5    78.7  56:44
                               79:21  78:22
4  HAsF.sub.6
       1.6   3.5    99.3  82:18
                               78:22  78:22
5  HPF.sub.6
       2     2      2.9   51:49
                               57:43  60:40
6  HPF.sub.6
       1.6   2      80.8  86:14
                               71:29  69:31
7  HSbF.sub.6
       2     3      98.3  48:52
                               75:25  74:26
8  HSbF.sub.6
       1.6   3      99.0  84:16
                               75:25  74:26
__________________________________________________________________________
Similar results were obtained when diisopropylethylamine 0.040 ml of a 0.1M solution; 20 mole % with respect to Ru(II)! was added to the hydrogenation medium. Improvement (of the order of 10%) of the cis/trans isomer ratio was then observed.
EXAMPLE 9
The activity of a variety of racemic or achiral catalysts according to the invention, prepared as described in example 1, using HBF4 as the acid (in the form of its etherate), and varying the ligand, was tested in the hydrogenation reaction of methyl 3-oxo-2-pentyl-1-cyclopentene-acetate.
All hydrogenations were carried out in dichloromethane and at room temperature. The results are given in the table. It should be noticed that these runs were not optimized, which explains the poor substrate conversions observed in some cases.
__________________________________________________________________________
                 Catalyst
                        Reaction
                             H.sub.2
                                  Conversion
                                        Isomer
                 concentration
                        time pressure
                                  of substrate
                                        ratio
Run
   Ligand        (mole %)
                        (h)  (10.sup.6 Pa)
                                  (%)   cis/trans
__________________________________________________________________________
1  L13 (n = 1)   2      4    5    9     94:6
2  L13 (n = 2)   2      6    5    18    96.6:3.4
3  L13 (n = 3)   2      6    5    18    96.6:3.4
4  L13 (n = 4)   2      4    5    35    98.8:1.2
5  L10 (R = C.sub.6 H.sub.5)
                 2      14.5 5    29    98:2
6  L10 (R = isopropyl)
                 1      3    5    53    98.9:1.1
7* L10 (R = isopropyl)
                 2      7.5  5    98.5  96.8:3.2
8  L10 (R = C.sub.2 H.sub.5)
                 1      17   5    4     81:19
9**
   L12 (R = C.sub.6 H.sub.5)
                 2      25   9    96    91.3:8.2
10 L8  R.sup.1 = Si(CH.sub.3).sub.3
                 2      5    5    30    98.3:1.7
       R.sup.2 = C.sub.6 H.sub.5
11 L8  R.sup.1 = Si(CH.sub.3).sub.3
                 2      22   9    92    97.0:3.0
       R.sup.2 = isopropyl
12 L8  R.sup.1 = Si(CH.sub.3).sub.3
                 1      8    4    43    98.3:1.7
       R.sup.2 = isopropyl
13 L8  R.sup.1 = CH.sub.3
                 2      24   9    15    94.4:5.6
       R.sup.2 = C.sub.6 H.sub.5
__________________________________________________________________________
 *25% of alcohols resulting from the reduction of Hedione ®
 (byproducts)
 **7% of alcohols resulting from the reduction of Hedione ®
 (byproducts)
EXAMPLE 10
A. In a glove box under argon, 4.05 g of HBF4.Et2 O (Et=C2 H5 ; 25.0 mmole, 3.40 ml) were introduced into a glass beaker using a pipette, then about 100 ml of dichloromethane were added. Thereafter the mixture was stirred to dissolve the etherate and the beaker was filled up to a volume of 250 ml. The 0.1M (moles/1) solution of HBF4.Et2 O thus obtained was used as such for the preparation of the catalyst.
B. In a glove box, 16.0 mg (0.050 mmole) of Ru(COD)(2-methallyl)2 ! and 15.0 mg (0.050 mmole) of (-)-Me-DuPHOS were mixed in a glass container and dissolved in 4 ml of CH2 Cl2. Thereafter, 1 ml (0.1 mmole) of the HBF4 etherate solution prepared in step A was added slowly (about 1 min) at room temperature via a syringe. The resulting red-brown solution containing about 0.01M (moles/1) of catalyst was allowed to stand for 2 h before use. The solution stays active for more than 1 week when kept in the glove box at room temperature.
C. Inside the glove box, 224 mg (1 mmole) of methyl 3-oxo-2-pentyl-1-cyclopentene-1-acetate were added to 2 ml of the catalytic solution obtained in step B (0.02 mmole, 2 mole % with respect to the substrate) in a glass beaker which can be transferred to an autoclave. The solution thus obtained was then transferred into an autoclave and stirred for 2 h at 90 bar (9×106 Pa) hydrogen pressure at room temperature. The autoclave was almost entirely degassed and opened inside the glove box. The yellow-orange reaction mixture was evaporated under vacuo to strip the dichloromethane. The solid residue and the yellow-orange liquid thus obtained were treated with pentane and the suspension filtered through a Teflon® filter of 0.22 μ to precipitate the catalyst. The remaining solid was washed with pentane and filtered through the same filter. The combined pentane solutions contained the desired Hedione® in a cis/trans ratio=98.5/1.5 and a ratio (+)-cis/(-)-cis=79/21.
D. A second hydrogenation cycle was carried out with the catalyst which had remained in the Teflon® filter. The latter was washed with 2 ml of CH2 Cl2 and the same dichloromethane used to dissolve the precipitate which had remained in the container. 224 mg of the substrate mentioned in C were added to this solution, which was thereafter hydrogenated as described in C to again obtain Hedione® with a cis/trans ratio of 98.8/1.2 and a (+)-cis/(-)-cis ratio of 79/21.
B'. According to an alternative embodiment to the one described under B, the catalyst was also prepared as follows: the HBF4.Et2 O solution in dichloromethane described under A was first added to (-)-Me-DuPHOS, and the ether and the dichloromethane were evaporated. The thus obtained solid of the onium salt of the ligand was then redissolved in pure dichloromethane and added to Ru(COD)(2-methallyl)2 !. The reaction occurs with release of isobutene. The catalyst thus obtained was used under conditions identical to those described under C to give (+)-cis-Hedione® having the same characteristics.
C' Results similar to those described under C were obtained when bis(2,4-dimethylpentadienyl)ruthenium (see, for example, L. Stahl et al., Organometallics, 1983, 2, 1229) or bis(2,4-dimethyl-1-oxapentadienyl)ruthenium (see T. Schmidt et al., J. Chem. Soc. Chem. Comm., 1991, 1427) were used for the preparation of the catalyst, instead of the complex Ru(COD)(2-methallyl)2 !.
C". Moreover, the use in the hydrogenation described under C of a catalyst prepared in a manner identical to that described under B but using as ligand (-)-JOSIPHOS (ligand L11, R=cyclohexyl, R'=phenyl; origin: STREM Chemicals Inc.) enabled the preparation of Hedione® with a cis/trans ratio of 98/2 and a (+)-cis/(-)-cis ratio of 77/23.
EXAMPLE 11
The reaction was carried out in a way similar to that described in Examples 10A to C, but using 4.171 g (13.056 mmole) of Ru(COD)(2-methallyl)2 !, 4.000 g (13.056 mmole) of (-)-Me-DuPHOS, 1000 g (4.458 mole) of methyl 3-oxo-2-pentyl-1-cyclopentene-1-acetate, 261 ml (26.10 mmole) of the 0,1M HBF4.Et2 O-solution in dichloromethane and 1.71 of CH2 Cl2.
The hydrogenation reaction was carried out at 7,5° C. and under a hydrogen pressure of 35 bar (3.5×106 Pa) for 24 h, under stirring (1000-2000 rpm).
After evaporation of the solvent, 1095 g of a brown product were obtained which were treated with pentane and the solution filtered as previously described. The combined pentane extracts were concentrated under vacuo to give 978 g of product, the thin-film distillation of which (Leybold type apparatus, 86°/0.1 mbar) gave 932 g of a colourless product consisting of the desired Hedione® having a cis/trans ratio of 98/2 and a (+)-cis/(-)-cis ratio of 85/15.

Claims (26)

We claim:
1. Ruthenium (II) catalyst comprising ligands formed of bidentate phosphines, characterized in that it is obtainable by a process which comprises treating an appropriate Ru(II) complex and a bidentate diphosphine ligand, present in equimolar amounts, with an acid of formula HX, wherein X is a non-coordinating anion, said acid being used in a ratio which does not exceed 2 molar equivalents per mole of the Ru(II) complex, the treatment being carried out in a non-coordinating or weakly coordinating medium and under an inert atmosphere.
2. Catalyst according to claim 1, characterized in that the Ru(II) complex is selected from the group of Ru(II) compounds of the type (diene)Ru(allyl)2 or bis(pentadienyl)Ru.
3. Catalyst according to claim 2, characterized in that the ruthenium complex is (COD)Ru(2-methallyl)2, bis(2,4-dimethylpentadienyl)Ru or bis(2,4-dimethyl-1-oxapentadienyl)Ru.
4. Catalyst according to claim 1, characterized in that the diphosphine ligand is selected from the group consisting of the chiral ligands known under the abbreviations of Me-DuPHOS, Et-DuPHOS, BINAP, To1BINAP, SKEWPHOS and JOSIPHOS.
5. Catalyst according to claim 4, characterized in that the bidentate phosphine ligand is selected from the group consisting of the chiral diphosphines known under the abbreviations of Me-DuPHOS, SKEWPHOS and JOSIPHOS.
6. Catalyst according to claim 5, characterized in that the ligand is (R,R)-(-)-Me-DuPHOS.
7. Catalyst according to claim 1, characterized in that the acid is selected from the group consisting of HBF4, HPF6, HSbF6, HAsF6, and HB{3,5-(CF3)2 C6 H4 }4.
8. Catalyst according to claim 7, characterized in that HBF4 is used in the form of its etherate.
9. Catalyst according to claim 7, characterized in that the acid is used in a proportion of 1.5 to 2 molar equivalents per mole of Ru(II) complex.
10. Catalyst according to claim 1, characterized in that the treatment is carried out in presence of a non-coordinating or weakly coordinating organic solvent and/or of a substrate of formula ##STR12## wherein R1 represents a linear or branched alkyl radical from C1 to C4 and R2 represents a saturated or unsaturated, linear or branched hydrocarbon rest from C1 to C8.
11. Catalyst characterized in that the treatment is carried out only in the presence of a substrate of formula (II) as defined in claim 10.
12. Catalyst according to claim 10, characterized in that the solvent is selected from the group consisting of dichloromethane, dichloroethane, methyl pivalate, methyl acetate, ethyl acetate, isopropyl acetate, acetone, 2-butanone, 3-pentanone and any mixture of said solvents.
13. Catalyst according to claim 12, characterized in that the solvent is or comprises dichloromethane.
14. Catalyst according to claim 10, characterized in that the substrate of formula (II) is methyl 3-oxo-2-pentyl-1-cyclopentene-1-acetate.
15. Catalyst according to claim 1, characterized in that the treatment is carried out at room temperature.
16. Process for the preparation of a catalyst of Ru(II), characterized in that equimolar amounts of an appropriate Ru(II) complex and of a bidentate phosphine ligand are reacted, under an inert atmosphere and in a non-coordinating or weakly coordinating medium, with an acid of formula HX, wherein X represents a non-coordinating anion, said acid being used in a proportion not exceeding 2 molar equivalents per mole of Ru(II) complex.
17. Process according to claim 16, characterized in that the reaction is carried out in the presence of an organic non-coordinating or weakly coordinating solvent and/or a substrate of formula ##STR13## wherein R1 is a linear or branched alkyl radical from C1 to C4 and R2 is a saturated or unsaturated, linear or branched hydrocarbon rest from C1 to C8.
18. Process for the preparation of a compound of formula ##STR14## wherein R1 represents a linear or branched alkyl radical from C1 to C4 and R2 represents a saturated or unsaturated, linear or branched hydrocarbon rest from C1 to C8, essentially in the form of the cis-configuration isomer, characterized in that a substrate of formula ##STR15## in which R1 and R2 have the meaning indicated above, is hydrogenated in the presence of a Ru(II) catalyst according to claims 1, at a hydrogen pressure from 10 to 100 bar.
19. Process according to claim 18, characterized in that there is used a catalyst comprising as a ligand an appropriate chiral diphosphine, to obtain compound (I) essentially in the form of an optically active isomer of (1R)-cis configuration.
20. Process according to claim 18, characterized in that the catalytic hydrogenation is carried out in a non-coordinating or weakly coordinating solvent under the reaction conditions.
21. Process according to any of claims 18, characterized in that the Ru(II) catalyst is formed in situ, optionally in the presence of the substrate of formula (II).
22. Process according to claim 20, characterized in that the non-coordinating solvent is selected from the group consisting of dichloromethane, dichloroethane, methyl pivalate, methyl acetate, ethyl acetate, isopropyl acetate, acetone, 2-butanone, 3-pentanone, and any mixture of said solvents.
23. Process according to any of claims 18, characterized in that the substrate of formula (II) is methyl 3-oxo-2-pentyl-1-cyclopentene-1-acetate and in that essentially methyl (+)-(1R)-cis-3-oxo-2-pentyl-1-cyclopentaneacetate is obtained.
24. Process according to claim 23, characterized in that the hydrogenation is carried out in the presence of a catalyst selected from the group consisting of the chiral diphosphines known under the abbreviations of Me-DuPHOS, Et-DuPHOS, BINAP, To1BINAP, SKEWPHOS, and JOSIPHOS.
25. Process according to any of claim 18, characterized in that the catalyst is present in a concentration from 0.1 to 2 mole %, with respect to the substrate.
26. A catalyst prepared by the process of claim 16.
US08/875,335 1995-11-22 1996-11-20 Ruthenium catalysts and their use in the asymmetric hydrogenation of cyclopentenones Expired - Lifetime US5874600A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CH330095 1995-11-22
CH3300/95 1995-11-22
CH162196 1996-06-28
CH1621/96 1996-06-28
PCT/IB1996/001263 WO1997018894A1 (en) 1995-11-22 1996-11-20 Ruthenium catalysts and use thereof in asymmetrical cyclopentenone hydrogenation

Publications (1)

Publication Number Publication Date
US5874600A true US5874600A (en) 1999-02-23

Family

ID=25688186

Family Applications (1)

Application Number Title Priority Date Filing Date
US08/875,335 Expired - Lifetime US5874600A (en) 1995-11-22 1996-11-20 Ruthenium catalysts and their use in the asymmetric hydrogenation of cyclopentenones

Country Status (6)

Country Link
US (1) US5874600A (en)
EP (1) EP0810903B1 (en)
JP (1) JP4063875B2 (en)
DE (1) DE69602586T2 (en)
ES (1) ES2136437T3 (en)
WO (1) WO1997018894A1 (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166257A (en) * 1996-06-28 2000-12-26 Rhodia Chimie Asymmetric hydrogenation method of a ketonic compound and derivative
WO2002057227A2 (en) * 2001-01-19 2002-07-25 Rhodia/Chirex, Inc. Process of enantiomerically enriched flavor and fragrance components
US6586620B1 (en) 1999-11-05 2003-07-01 Firmenich Sa Process for the preparation of alkyl 3-oxo-2-pentyl-1-cyclopenteneacetates
US20030144138A1 (en) * 2001-12-10 2003-07-31 Kazuhiko Matsumura Novel asymmetric phosphine ligand
US20070015925A1 (en) * 2003-05-09 2007-01-18 Martin Kesselgruber Phospholane salts and their use in enantioselective hydrogenation
US20070014919A1 (en) * 2005-07-15 2007-01-18 Jani Hamalainen Atomic layer deposition of noble metal oxides
US20070238892A1 (en) * 2002-09-26 2007-10-11 Eit Drent Process for the hydroformylation of an ethylenically unsaturated compound
US20080146042A1 (en) * 2000-05-15 2008-06-19 Asm International N.V. Method of growing electrical conductors
US20080318417A1 (en) * 2006-09-01 2008-12-25 Asm Japan K.K. Method of forming ruthenium film for metal wiring structure
US20090036692A1 (en) * 2005-06-30 2009-02-05 Asahi Kasei Chemicals Corporation Process for Production of Substituted Cyclopentanone
US20090087339A1 (en) * 2007-09-28 2009-04-02 Asm Japan K.K. METHOD FOR FORMING RUTHENIUM COMPLEX FILM USING Beta-DIKETONE-COORDINATED RUTHENIUM PRECURSOR
US20110020546A1 (en) * 2009-05-15 2011-01-27 Asm International N.V. Low Temperature ALD of Noble Metals
US20110166360A1 (en) * 2008-03-13 2011-07-07 Bial - Portela & Ca, S.A. Catalytic Process for Asymmetric Hydrogenation
US8025922B2 (en) 2005-03-15 2011-09-27 Asm International N.V. Enhanced deposition of noble metals
US8084104B2 (en) 2008-08-29 2011-12-27 Asm Japan K.K. Atomic composition controlled ruthenium alloy film formed by plasma-enhanced atomic layer deposition
US8927403B2 (en) 2005-03-15 2015-01-06 Asm International N.V. Selective deposition of noble metal thin films
US9129897B2 (en) 2008-12-19 2015-09-08 Asm International N.V. Metal silicide, metal germanide, methods for making the same
US9379011B2 (en) 2008-12-19 2016-06-28 Asm International N.V. Methods for depositing nickel films and for making nickel silicide and nickel germanide
US9607842B1 (en) 2015-10-02 2017-03-28 Asm Ip Holding B.V. Methods of forming metal silicides
WO2018183788A1 (en) 2017-03-31 2018-10-04 International Flavors & Fragrances Inc. Chemical process of preparing dehydrohedione

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214763B1 (en) 1997-05-20 2001-04-10 Firmenich Sa Ruthenium catalysts and their use in the asymmetric hydrogenation of weakly coordinating substrates
ES2212287T3 (en) * 1997-05-20 2004-07-16 Firmenich Sa RUTENIUM CATALYSTS AND THEIR USE IN THE ASYMMETRIC HYDROGENATION OF WEAKLY COORDINATING SUBSTRATES.
NL1007776C2 (en) * 1997-12-12 1999-06-15 Dsm Nv Catalysts for asymmetric synthesis of optically active products with high enantiomeric excess
WO1999031041A1 (en) * 1997-12-17 1999-06-24 Chirotech Technology Limited Asymmetric hydrogenation
GB9807888D0 (en) 1998-04-09 1998-06-10 Chirotech Technology Ltd Asymmetric hydrogenation
EP1070043B1 (en) * 1998-04-09 2004-02-18 Chirotech Technology Limited Asymmetric hydrogenation
US6280519B1 (en) * 1998-05-05 2001-08-28 Exxon Chemical Patents Inc. Environmentally preferred fluids and fluid blends
JP4667027B2 (en) * 2004-12-09 2011-04-06 旭化成イーマテリアルズ株式会社 Process for producing cis-2,3-disubstituted cyclopentanone

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6918228A (en) * 1969-12-04 1971-06-08 Aliphatic keto-esters used in perfumes
WO1991002588A1 (en) * 1989-08-23 1991-03-07 Societe National Elf Aquitaine Improvement to the preparation of chiral catalysts based on ruthenium and phosphorus complexes
EP0470756A2 (en) * 1990-08-01 1992-02-12 Takasago International Corporation Ruthenium-phosphine complex useful as catalyst and intermediate for synthesis thereof
FR2693190A1 (en) * 1992-07-02 1994-01-07 Elf Aquitaine A process for the enantioselective hydrogenation of the C = O OXO double bond.
WO1996000206A1 (en) * 1994-06-23 1996-01-04 Firmenich S.A. Method for preparing (+)-(1r)-cis-3-oxo-2-pentyl-1-cyclopentaneacetic acid

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304524A (en) * 1991-06-17 1994-04-19 Ethyl Corporation Asymmetric hydrogenation of aromatic-substituted olefins using organoruthenium catalyst

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6918228A (en) * 1969-12-04 1971-06-08 Aliphatic keto-esters used in perfumes
WO1991002588A1 (en) * 1989-08-23 1991-03-07 Societe National Elf Aquitaine Improvement to the preparation of chiral catalysts based on ruthenium and phosphorus complexes
EP0470756A2 (en) * 1990-08-01 1992-02-12 Takasago International Corporation Ruthenium-phosphine complex useful as catalyst and intermediate for synthesis thereof
FR2693190A1 (en) * 1992-07-02 1994-01-07 Elf Aquitaine A process for the enantioselective hydrogenation of the C = O OXO double bond.
WO1996000206A1 (en) * 1994-06-23 1996-01-04 Firmenich S.A. Method for preparing (+)-(1r)-cis-3-oxo-2-pentyl-1-cyclopentaneacetic acid

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166257A (en) * 1996-06-28 2000-12-26 Rhodia Chimie Asymmetric hydrogenation method of a ketonic compound and derivative
US6586620B1 (en) 1999-11-05 2003-07-01 Firmenich Sa Process for the preparation of alkyl 3-oxo-2-pentyl-1-cyclopenteneacetates
US7955979B2 (en) 2000-05-15 2011-06-07 Asm International N.V. Method of growing electrical conductors
US8536058B2 (en) 2000-05-15 2013-09-17 Asm International N.V. Method of growing electrical conductors
US20080146042A1 (en) * 2000-05-15 2008-06-19 Asm International N.V. Method of growing electrical conductors
WO2002057227A2 (en) * 2001-01-19 2002-07-25 Rhodia/Chirex, Inc. Process of enantiomerically enriched flavor and fragrance components
WO2002057227A3 (en) * 2001-01-19 2002-11-07 Rhodia Chirex Inc Process of enantiomerically enriched flavor and fragrance components
US20030144138A1 (en) * 2001-12-10 2003-07-31 Kazuhiko Matsumura Novel asymmetric phosphine ligand
US6624320B2 (en) * 2001-12-10 2003-09-23 Takasago International Corporation Asymmetric phosphine ligand
US20070238892A1 (en) * 2002-09-26 2007-10-11 Eit Drent Process for the hydroformylation of an ethylenically unsaturated compound
US7414155B2 (en) * 2002-09-26 2008-08-19 Shell Oil Company Process for the hydroformylation of an ethylenically unsaturated compound
US7491671B2 (en) * 2003-05-09 2009-02-17 Solvias Ag Phospholane salts and their use in enantioselective hydrogenation
US20070015925A1 (en) * 2003-05-09 2007-01-18 Martin Kesselgruber Phospholane salts and their use in enantioselective hydrogenation
US8025922B2 (en) 2005-03-15 2011-09-27 Asm International N.V. Enhanced deposition of noble metals
US8927403B2 (en) 2005-03-15 2015-01-06 Asm International N.V. Selective deposition of noble metal thin films
US9587307B2 (en) 2005-03-15 2017-03-07 Asm International N.V. Enhanced deposition of noble metals
US9469899B2 (en) 2005-03-15 2016-10-18 Asm International N.V. Selective deposition of noble metal thin films
US8501275B2 (en) 2005-03-15 2013-08-06 Asm International N.V. Enhanced deposition of noble metals
KR100960250B1 (en) 2005-06-30 2010-06-01 아사히 가세이 케미칼즈 가부시키가이샤 Process for production of substituted cyclopentanone
US7897802B2 (en) * 2005-06-30 2011-03-01 Asahi Kasei Chemicals Corporation Process for production of substituted cyclopentanone
US20090036692A1 (en) * 2005-06-30 2009-02-05 Asahi Kasei Chemicals Corporation Process for Production of Substituted Cyclopentanone
US20070014919A1 (en) * 2005-07-15 2007-01-18 Jani Hamalainen Atomic layer deposition of noble metal oxides
US20080318417A1 (en) * 2006-09-01 2008-12-25 Asm Japan K.K. Method of forming ruthenium film for metal wiring structure
US20090087339A1 (en) * 2007-09-28 2009-04-02 Asm Japan K.K. METHOD FOR FORMING RUTHENIUM COMPLEX FILM USING Beta-DIKETONE-COORDINATED RUTHENIUM PRECURSOR
US20110166360A1 (en) * 2008-03-13 2011-07-07 Bial - Portela & Ca, S.A. Catalytic Process for Asymmetric Hydrogenation
US8084104B2 (en) 2008-08-29 2011-12-27 Asm Japan K.K. Atomic composition controlled ruthenium alloy film formed by plasma-enhanced atomic layer deposition
US9129897B2 (en) 2008-12-19 2015-09-08 Asm International N.V. Metal silicide, metal germanide, methods for making the same
US9379011B2 (en) 2008-12-19 2016-06-28 Asm International N.V. Methods for depositing nickel films and for making nickel silicide and nickel germanide
US9634106B2 (en) 2008-12-19 2017-04-25 Asm International N.V. Doped metal germanide and methods for making the same
US10553440B2 (en) 2008-12-19 2020-02-04 Asm International N.V. Methods for depositing nickel films and for making nickel silicide and nickel germanide
US20110020546A1 (en) * 2009-05-15 2011-01-27 Asm International N.V. Low Temperature ALD of Noble Metals
US10043880B2 (en) 2011-04-22 2018-08-07 Asm International N.V. Metal silicide, metal germanide, methods for making the same
US9607842B1 (en) 2015-10-02 2017-03-28 Asm Ip Holding B.V. Methods of forming metal silicides
US10199234B2 (en) 2015-10-02 2019-02-05 Asm Ip Holding B.V. Methods of forming metal silicides
WO2018183788A1 (en) 2017-03-31 2018-10-04 International Flavors & Fragrances Inc. Chemical process of preparing dehydrohedione
US11198667B2 (en) 2017-03-31 2021-12-14 International Flavors & Fragrances Inc. Chemical process of preparing dehydrohedione

Also Published As

Publication number Publication date
JP4063875B2 (en) 2008-03-19
DE69602586T2 (en) 2000-03-02
JPH10513402A (en) 1998-12-22
EP0810903B1 (en) 1999-05-26
DE69602586D1 (en) 1999-07-01
EP0810903A1 (en) 1997-12-10
ES2136437T3 (en) 1999-11-16
WO1997018894A1 (en) 1997-05-29

Similar Documents

Publication Publication Date Title
US5874600A (en) Ruthenium catalysts and their use in the asymmetric hydrogenation of cyclopentenones
Fritschi et al. Semicorrin metal complexes as enantioselective catalysts. Part 2. Enantioselective cyclopropane formation from olefins with diazo compounds catalyzed by chiral (semicorrinato) copper complexes
WO1993001199A1 (en) Chiral phospholanes via chiral 1,4-diol cyclic sulfates
Akotsi et al. Versatile precursor to ruthenium‐bis (phosphine) hydrogenation catalysts
Zanetti et al. Synthesis, characterization, and application in asymmetric hydrogenation reactions of chiral ruthenium (II) diphosphine complexes
US6455460B1 (en) Ruthenium catalysts and method for making same
DE69919256T2 (en) Ruthenium phosphine complex and process for its preparation
JP2739254B2 (en) Iridium-optically active phosphine complex and method for producing optically active alcohol using the same
EP1622920B1 (en) Substituted ferrocenyldiphosphines as ligands for homogeneous hydrogenation catalysts
US6583312B2 (en) Process for preparing optically active trimethyllactic acid and its esters
EP1127061B1 (en) Chiral ligands for asymmetric catalysis
EP0920354B1 (en) Ruthenium catalysts and their use in the asymmetric hydrogenation of weakly coordinating substrates
WO2005032712A1 (en) Process for preparing cationic rhodium complexes
US4870208A (en) Asymmetric hydrogenolysis of epoxides
JP3159661B2 (en) Method for producing optically active alcohols
CN112824423A (en) Chiral ferrocenylphosphine-indolylaminophosphine ligand and preparation method and application thereof
US5352836A (en) Enantioselective lewis acid catalysts of the early transition metals
EP1245551B1 (en) 1,2-bis(methyl(1,1,3,3-tetramethylbutyl)-phosphino)ethane, process for the preparation thereof, transition metal complexes containing the same as the ligand and uses thereof
DE10157533A1 (en) Process for the preparation of chiral, non-racemic 5-substituted gamma-butyrolactones

Legal Events

Date Code Title Description
AS Assignment

Owner name: FIRMENICH S.A., SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RAUTENSTRAUCH, VALENTIN;VANHESSCHE, P.M.;GENET, JEAN-PIERRE;AND OTHERS;REEL/FRAME:008780/0304;SIGNING DATES FROM 19970605 TO 19970619

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCF Information on status: patent grant

Free format text: PATENTED CASE

CC Certificate of correction
CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FEPP Fee payment procedure

Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 12